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The components of the cardiopulmonary bypass system, the prime volume and the 
techniques of perfusion are believed to have a significant impact on postoperative 
morbidity and even mortality in pediatric heart surgery. Complete repair of congenital 
heart defects is increasingly performed in neonates and small infants with a weight of 
ranging between two and five kilogram. The consequences of CPB are more pronounced 
because of the immaturity of their organs and the discrepancy between prime volume of 
the CPB system and patient blood volume. CPB results in a systemic inflammatory 
response syndrome (SIRS) [1]. SIRS is a nonspecific inflammation process that can lead 
to capillary leakage. Capillary leakage results in an extravascular fluid accumulation. 
When the extravascular fluid accumulation is severe the interstitial edema that occurs can 
lead to end organ dysfunction [1, 2]. The CPB system is seen as the main activator of the 
inflammatory response. However, several other factors play a role in the activation of  the 
inflammatory response such as surgical trauma, thrombin activation, ischemia-
reperfusion injury and blood-air contact [3-5]. The degree of hemodilution is another 
factor [6]. 
Miniaturization of all components of the bypass system leads to lower prime volumes, 
resulting in a reduced hemodilution factor [2, 5]. The extent of the dilution factor 
contributes to the capillary leakage due to complement activation. Böning et al. showed 
that a large prime volume leads to an increase in IL-6 production and tumor necrosis 
factor-  [6]. A Low prime volume results in less use of donor blood during and after CPB 
as the dilution factor affects postoperative blood loss ass well [7]. The disadvantages of 
donor blood are well known: the risk of virus and prion transfer, depression of the 
immune system, delayed haemolysis and the metabolic load, low pH, high glucose and 
potassium concentrations, of stored blood. It should be mentioned that also in fresh red 
blood cells (< 5 days) a low pH and a high glucose concentration is found [8]. This 
metabolic overload can be avoided by washing the donor red cells using a cell saver. 
Swindell et al. showed that washing of donor blood reduces potassium and lactate loads 
during CPB [9].
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The aim of this thesis was to investigate several techniques or adaptations that were 
developed to reduce the deleterious effects of CPB in neonates and infants. 
Ultrafiltration (UF) is widely used during and after CPB to reduce the total body water 
increase, to reduce the need for donor blood and to remove some inflammatory mediators 
[10, 11, 12]. There has to be a minimal volume in the venous reservoir to for optimal 
bloodflow; this limits the efficiency of UF performed during CPB.  [10]. Zero-balanced 
ultrafiltration (Z-BUF) or dilutional ultrafiltration (DCUF) is developed especially to 
remove some proinflammatory mediators during CPB; fluid is added to the venous 
reservoir continuously [11, 13].
Modified ultrafiltration (MUF) is a technique described for the first time in 1991 by Naik 
and Elliott [10]. MUF was especially developed to diminish the effects of hemodilution 
thereby increasing hemoglobin and hematocrit values without the use of donor blood. 
MUF permits the return of the concentrated residual volume of the CPB system. MUF is 
performed after cessation of CPB, but before the administration of protamin. There are 
several techniques to perform MUF, arterial-venous, venous-venous or venous-arterial 
[14]. The arterial-venous method has the preference above the other techniques because 
warm oxygenized blood is presented to the lungs. This results immediately to a decrease 
in pulmonary vascular resistance and stabilizes hemodynamic conditions during the MUF 
procedure [15]. Other reported effects of MUF are an immediate rise in systolic blood 
pressure, improved ventricular function, as well as a decreased need for blood transfusion 
due to an increase of hematocrit and a decrease of postoperative bleeding [16].
We studied a group of 198 patients retrospectively on the effects of MUF on donor blood 
use and postoperative blood loss. We investigated whether MUF was able to reduce the 
use of donor blood and the influence of MUF on postoperative chest drain loss. This 
study is presented in chapter 2. 
In chapter 3 and 4 we describe the anti-oxidative capacity of the CPB prime used for 
neonates. Pyles et al. described a decrease of the antioxidant capacity of plasma after 
CPB in children [17]. It has been reported that neonates and infants have a poor 
antioxidative capacity and a low iron binding capacity [18]. Transfusion of a relatively 
small volume of fluid with a low antioxidant capacity decreases the ability of the plasma 
to catabolize reactive oxygen species [19]. Because of the relative large prime volume of 
the bypass system compared to the circulating volume of the patient, the composition of 
the prime therefore may play an important role in increasing the anti-oxidative capacity 
and thereby preventing reactive oxygen species (ROS) formation. ROS activates nuclear 
factor – B, which is an important protein in the regulation of the acute phase response of 
inflammation. Nuclear factor – B stimulates the production of, among others, IL-1, IL-6, 
and tumor necrosis factor-  [20]. We compared in vitro two different prime 
compositions, one prime solution based on human albumin and second prime solution 
based on fresh frozen plasma. Of both primes the total antioxidant capacity, as well as 
that of selected individual antioxidants was measured. We also measured the release of 
the important prooxidants non-protein bound iron and Hb/haem in both primes. 
The CPB system is believed to be the main activator of the SIRS. Coatings of the 
different components of the bypass system are developed to reduce the contact activation 
between blood and the surface of the bypass system. Several coatings are commercially 
available: human albumin coating, heparin coatings, trillium coating and 
phosphorylcholine coating. A lot of controversies are found in the literature concerning 
coating of CPB systems. It is difficult to compare the different studies because of the 
differences in methods and composition of the study groups. In several studies children 
with a bodyweight of less then 5 kilogram are compared to children weighing more than 
15 kilograms. Furthermore different coatings are used and the measured parameters are 
numerous. All over it appears that most coatings preserve platelets but do not completely 
inhibit the inflammatory response [21]. This is due to the fact that the CPB system is only 
one of the many triggers of the inflammatory response. Children undergoing major heart 
surgery without CPB compared with children undergoing heart surgery with the use of 
CPB are showing a simulair SIRS reaction [4]. The results of our prospective blind 
randomized study comparing uncoated to PHISIO® coated CPB systems in neonates and 
infants with very strict inclusion criteria on bodyweight, cyanoses and syndromes are 
described in chapter 5. 
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There is lack of information as to the interaction between the coating of the CPB system 
and medication. Mehta and colleagues describe the loss of several medications during 
time in an in vitro extracorporeal membrane oxygenation circuit [22].
The use of corticosteroids in pediatric cardiac surgery is controversial. Corticosteroids are 
sometimes used in pediatric cardiac surgery to reduce the pro-inflammatory mediators. 
The timing of administration seems to be important [23]. When corticosteroids are given 
before start the of CPB and during CPB, the concentration of proinflammatory cytokines 
has been reported to decrease [24]. For this reason corticosteroids are added to the prime 
in the same amount as the quantity that is given intravenously to the patient. We 
investigated whether dexamethasone concentration decreased during recirculation of the 
prime in an in vitro setting both with coated and with uncoated systems. The results are 
described in chapter 6.
Many of the questions that are described in this introduction section are also discussed in 
chapter 7 (review article). 
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Abstract
Background. Cardiopulmonary bypass in children results in considerable water retention, 
especially in neonates and small infants. Dilution of plasma proteins increases water loss 
into the extravascular compartments. Excessive total body water may prolong ventilatory 
support and may contribute to a prolongation of intensive care convalescence. After 
discontinuation of cardiopulmonary 
bypass, modified ultrafiltration can be used to withdraw plasma water from the total 
circulating volume. 
Methods. This retrospective study included 198 pediatric patients who underwent cardiac 
operations in the period from September 1991 to November 1994. Two groups were 
compared: 99 patients without ultrafiltration and 99 patients receiving modified 
ultrafiltration. The following indices were analyzed: cardiopulmonary bypass prime 
volume, transfused blood volume during and after the operation, postoperative chest 
drain loss, and hemoglobin and hematocrit levels before, during, and after the procedure. 
Results. Modified ultrafiltration resulted in a significant increase in hemoglobin and 
hematocrit levels and a significantly lower amount of transfused blood. Mean 
postoperative chest drain loss was significantly less in the patients who underwent 
modified ultrafiltration.
Conclusions. Modified ultrafiltration decreases blood transfusion requirements and chest 
drain loss after pediatric cardiac surgical procedures. 
Introduction
Cardiopulmonary bypass (CPB) with hypothermia and hemodilution results in an 
increase of total body water. Water retention is especially important in neonates and 
infants. The ratio of prime volume to patient blood volume is greater in smaller patients. 
Hemodilution increases tissue perfusion during CPB and allows the use of hypothermia, 
which is needed to protect against ischemic organ damage during periods of low flow and 
circulatory arrest [1]. Hemodilution also reduces donor blood requirements during CPB. 
Dilution of plasma proteins increases water loss into the extravascular compartment and 
postoperative blood loss as a result of clotting disturbances [2]. Cardiopulmonary bypass 
itself produces an important inflammatory response, and this "whole body inflammatory 
response" is especially large in children [3]. One of the consequences of this 
inflammatory reaction is increased capillary leakage. Higher capillary permeability 
accounts for an increase in total body water, especially in the extracellular interstitial 
compartment. All of these factors may have negative consequences in the postoperative 
course. Renal immaturity together with decreased cardiac output further delays the return 
to normal body water content. Intravenous diuretics and inotropic agents frequently are 
necessary in the younger age group to reduce the increase in total body water. If diuresis 
is inadequate, peritoneal dialysis may be needed temporarily. To avoid an excessive 
increase in body water while aiming to reduce the use of blood products as much as 
possible, synthetic large molecular substances are added to the CPB prime to increase the 
colloid osmotic pressure. Conventional ultrafiltration during CPB to reduce excess 
water is limited by the need to maintain a minimum level in the venous CPB reservoir. 
This is especially true in pediatric CPB because lower prime volumes are used. Naik 
and Elliott [4] could not demonstrate a significant effect of conventional ultrafiltration on 
reduction of the total body water increase and donor blood requirements. Using 
ultrafiltration immediately after the cessation of CPB (modified ultrafiltration, MUF) 
they were able to diminish significantly the total body water increase and donor blood 
requirements [4]. Another advantage of MUF over conventional ultrafiltration is its 
ability to return the contents of the CPB circuit to the patient in a concentrated form. 
In this study, we compared two groups of 99 patients each who underwent pediatric 
cardiac operations in our institution. In one group we used MUF; in the other group 
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ultrafiltration was not used. The technique of MUF is described and its effects are 
evaluated on total donor blood use, postoperative chest drain blood loss, and 
preoperative, perioperative, and postoperative hemoglobin and hematocrit levels. 
Material and Methods 
The study included 198 patients who underwent cardiac operations with CPB from 
September 1991 to November1994. Two longitudinal cohorts were studied. The first 
cohort had procedures between September 1991 and July 1993, at which point MUF was 
introduced and used in all pediatric patients operated on thereafter. The second cohort 
consisted of patients operated on from July 1993 to November 1994. In the first 99 
patients, no ultrafiltration was used; MUF was used in the second group of 99 patients. 
The two groups were comparable in sex, age, and body weight, as well as the duration of 
CPB. Preoperative values of hemoglobin and hematocrit were comparable (Table 1).  
Table 1. Patient Characteristicsa
Characteristic   No UF   Modified UF   p Valueb
Sex (male/female)   50/49    55/44    ... 
Mean age (mo)   33.6 + 3.94   31.8 + 3.52   0.73 
Mean weight (kg)   11.5 + 0.75   11.1 + 0.65   0.67 
Mean CPB time (min)  114 + 7.25   125 + 7.30   0.26 
Mean preoperative
     hemoglobin (mmol/L)  8.0 + 0.13   8.1 + 0.14   0.54 
Mean preoperative
hematocrit (%)  39 + 1    39 + 1    0.47 
aData are presented as n or mean + SEM. bStudent's t test or 2  test. CPB = cardiopulmonary bypass; MUF 
= modified ultrafiltration; UF = ultrafiltration. 
Diagnoses did not differ between the groups (Table 2). Methods of surgery and anesthetic 
techniques essentially did not change during the study period. No changes in perfusion 
techniques concerning prime solutions or blood transfusion policy occurred in our unit 
from September 1991 to November 1994. Aprotinin (Bayer AG, Germany) is not used in 
our institution for pediatric cardiac operations. Conventional ultrafiltration also was not 
used in our unit for these procedures.
Table 2. Patient Diagnoses 
Diagnosis    No UF   MUF
ASD     18    14 
VSD     29    21 
AVSD    8    11 
Tetralogy of Fallot   17    19 
TAPVC    3    3 
PA + IVS    ...    2 
Aortic stenosis   3    5 
Aortic insufficiency (+ VSD) ...    2 
Mitral stenosis   ...    1 
Mitral insufficiency   5    4 
Monoventricular
malformation  1    5 
TGA/DORV    9    5 
VSD + CoAo    ...    1 
VSD + IAA    1    ... 
AVSD + CoAo   1    1 
Miscellaneous   4    5 
ASD = atrial septal defect; AVSD = atrioventricular septal defect; CoAo = coarctation of the aorta; DORV 
= double outlet right ventricle; IAA = interrupted aortic arch; MUF = modified ultrafiltration; PA + WS = 
pulmonary atresia with intact ventricular septum; 
TAPVC = total anomalous pulmonary venous connection; TGA = transposition of the great arteries; UF = 
ultrafiltration; VSD = ventricular septal defect. 
A Dideco (Dideco, Mirandola, Italy) 701 oxygenator was used for patients with a weight 
up to 14 kg. For patients with a body weight between 14 and 35 kg, a Dideco 702 
oxygenator was used. The prime volume of the CPB circuit with the Dideco 701 
oxygenator was 650 mL, whereas the prime volume of the system with the Dideco 702 
oxygenator was 750 mL. The calculated volume of red blood cells needed for CPB circuit 
priming was deduced from the following formula: 
TBV = Ht2 x (Cv + CPBv) – (Ht1 x Cv) / Httbv
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where Cv = circulating volume (weight [kg] × 80 mL); CPBv = prime volume in the CPB 
circuit (mL); Ht1 = preoperative hematocrit; Ht2 = target hematocrit during 
CPB; HtTBV = hematocrit of transfused blood; and TBV = transfused blood volume (mL). 
The pH was corrected with 10 mL NaHCO3 8.4% for every 250 mL of red blood cell 
volume. One hundred milliliters of human albumin 20% solution (CLB, Amsterdam, 
the Netherlands) was added, using Ringer's solution to complete the CPB priming 
volume. Mannitol was substituted in a dose of 0.5 g per kilogram of body weight. 
A Minntech Hemocor HPH hemoconcentrator (Minntech Corporation, Minneapolis, MN) 
was used for MUF. In the patients with a body weight up to 14 kg, we used the Minntech 
HPH 400 ultrafilter with a prime volume of 27 mL. In the group of patients with a body 
weight from 14 to 35 kg, the Minntech HPH 600 ultrafilter with a prime volume of 43 
mL was used, as the higher circulating volume in these patients necessitated a filter with 
a higher filtration rate. The molecular cutoff weight of both ultrafilters is 65,000 D. 
The ultrafilter was primed together with the rest of the CPB circuit. The arterial cannula 
was connected to the inlet of the ultrafilter while the venous cannula was in connection 
with the outlet of the ultrafilter. During CPB, the inlet of the ultrafilter is partially 
clamped to allow limited flow through the filter (Fig 1). In this setup, conventional 
ultrafiltration is possible. Immediately after discontinuation of CPB, both cannulas 
remain in situ, the inlet is completely opened, and blood flows from the patient through 
the arterial cannula with the aid of a roller pump through the ultrafilter and back to the 
patient through the venous cannula (Fig 2). Our method of MUF leaves the arterial and 
one venous cannula in situ, whereas other groups replace the venous cannula for the 
purpose of MUF [4]. During MUF, the remainder of the volume in the CPB circuit is 
gradually remitted to the patient after having been concentrated by passage through the 
ultrafilter. The outlet of the ultrafilter may be partially clamped to allow a higher 
transmembrane pressure and a higher ultrafiltration rate. No vacuum suction is used. The 
volume loss in the venous reservoir is replaced first by the blood remaining in the venous 
tubing and later by added Ringer's solution. Modified ultrafiltration is finished when the 
residual fluid in the CPB circuit is almost completely replaced by clear Ringer's solution. 
Because the CPB system always remains fully primed, CPB can be restarted at any 
moment. 
The following variables were noted and compared in both groups: CPB prime volume, 
red blood cell transfusion volume (total amount and the volumes transfused during and 
after the operation), hemoglobin and hematocrit levels (before, during, and after CPB as 
well as immediately after MUF and, for both groups, at 4 hours after arrival of the patient 
to the intensive care unit), and volume of postoperative chest drain loss.
Statistical analysis of the compared variables was with the Student's t test for all variables 
with the exception of the sex differences between the two cohorts, for which the 2 test 
was used. A p value of 0.05 or less was regarded as statistically significant (A. H. 
Zwinderman, PhD, Department of Medical Statistics, Leiden University). 
Fig 1. Placement and blood flow of the ultrafilter in the circuit during 
cardiopulmonary bypass. (Ao = aorta; R.A. = right atrium; ven. res. = 
venous reservoir.) 
Fig 2. Placement and blood flow of the ultrafilter during 
modified ultrafiltration. (Ao = aorta, R.A. = right atrium; 
ven.res. = venous reservoir.) 
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Results
Mean CPB prime volumes were larger in the MUF group, with a mean (+ standard error 
of the mean [SEM]) volume of 707 + 7.89 mL in the group without ultrafiltration 
and 809 + 8.64 mL (p < 0.01) in the group with MUF. This difference is attributed 
exclusively to the volume needed to fill the ultrafilter and the extra tubing required for 
MUF.
Table 3. Red Blood Cell Transfusiona
Transfusion     No UF   MUF    p Valueb
Mean RBC volume     
transfused during CPB (mL) 173 ± 10.41   157 + 10.52   0.26 
Mean RBC volume  
transfused after CPB (mL)  147 ± 13.43   109 + 9.17   <0.05 
Mean total RBC
volume transfused (mL)  318 + 16.78   267 + 11.89   <0.05 
aData are presented as mean + SEM. bStudent's t test. 
CPB = cardiopulmonary bypass; MUF = modified ultrafiltration; RBC = red blood cell; UF = 
ultrafiltration. 
Fig 3. (A) Red blood cell volume transfused during cardiopulmonary bypass. (B) Red blood cell volume 
transfused after cardiopulmonary bypass. (C) Total transfused red blood cell volume. (MUF = modified 
ultrafiltration; UF = ultrafiltration.) 
No difference was found between the groups for the red blood cell volume supplied 
during the operation. However, postoperative red blood cell transfusion was significantly 
less frequent in the group receiving MUF. The total of perioperative red blood cell 
transfusions was also lower in the group with MUF (Table 3; Fig 3). 
Mean postoperative chest drain loss was significantly less in the patients who underwent 
MUF: 20.1 + 1.57 versus 29.1 + 3.67 mL/kg (p < 0.05).
Preoperative hemoglobin and hematocrit levels did not differ between the groups (see 
Table 1). During CPB, the mean values of hemoglobin and hematocrit were lower for the 
group having MUF (p < 0.05). After discontinuation of CPB, the hemoglobin and 
hematocrit levels did not change in the group in which MUF was not used. Red blood cell 
transfusions were used in the early postoperative period to increase the hemoglobin 
concentration to a target level of 7.0 mmol/L in all patients. Modified ultrafiltration 
resulted in a significant rise of hemoglobin and hematocrit levels (p < 0.001). Early red 
blood cell transfusion could therefore be avoided in most patients in the MUF group. 
Hemoglobin and hematocrit values 4 hours after arrival to the intensive care unit were not 
different for both groups, as a result of blood transfusion in the group of patients without 
MUF (Table 4; Fig 4). 
Table 4. Hemoglobin and Hematocrit Values During and After the Operationa
Measurement     No UF  MUF   p Valueb
Mean hemoglobin  
    during CPB (mmol/L)   5.2 + 0.09  4.9 + 0.06  <0.05 
Mean hematocrit during  
    CPB (%)    25 + 5   24 + 3   <0.05 
Mean hemoglobin after  
    CPB/MUF (mmol/L)c   5.2 + 0.09  6.7 ± 0.10  <0.001 
Mean hematocrit after  
    CPB/MUF (%)c   25 + 5   33 + 5   <0.001
Mean hemoglobin 4 h  
    after arrival at ICU (mmol/L)  6.8 + 0.12  6.6 + 0.09  0.24 
Mean hematocrit 4 h  
    after arrival at ICU (%)  33 + 6   32 + 5   0.20 
aData are presented as mean + SEM. bStudent's t test. cIn the group with no ultrafiltration, values were 
measured after discontinuation of CPB; in the group with MUF, values were measured after MUF.  
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Fig 4. (A) Course of hemoglobin (Hb) levels. (B) 
Course of hematocrit (Ht) levels. (CPB = 
cardiopulmonary bypass; ICU = intensive care unit; 
MUF = modified ultrafiltration; UF = ultrafiltration.) 
Hb (mmol/I) 
Discussion
The findings that the use of MUF after cessation of CPB increases hemoglobin and 
hematocrit levels and reduces postoperative chest drain loss and blood transfusion 
requirements have been described by Naik and Elliott [4]. Our study confirms these 
results and encourages us to continue using the MUF technique.
Modified ultrafiltration removes water from the circulating volume, leading to an 
immediate increase in hemoglobin and hematocrit levels. Removing water from the 
circulation gives us the opportunity to return almost entirely the volume of the CPB 
circuit to the patient. The need for blood transfusion decreases significantly, as does 
postoperative blood loss. 
In many patients, mean blood pressures increased during MUF. This has also been 
observed by others [4, 5]. The rise in blood viscosity due to water loss may be 
responsible for this blood pressure increase. Another explanation may be found in the 
removal of vasoreactive substances by MUF. Inflammatory mediators such as 
interleukins, tumor necrosis factor, and activated complement components, many of them 
having cardiodepressive characteristics, are reported to be removed by ultrafiltration [6, 
7].
We did not measure total body water content, but others have reported significant 
decreases in total body water using MUF [5]. The problem of excess water is especially 
important after neonatal cardiac procedures. In the pre-MUF period (before July 1993), 
we observed this problem much more often than in the patients in whom MUF was used 
(after July 1993). 
Modified ultrafiltration is a useful tool to combat water retention after pediatric cardiac 
operations. It diminishes the need for blood transfusion by both removing excess water 
and returning all CPB blood to the patient in a concentrated form. It also decreases 
postoperative chest drain loss. Of course, the use of MUF does not reduce the need for 
further efforts to limit the CPB prime volume to diminish water overload while at the 
same time trying to restrict the use of blood and blood products as much as possible. Our 
CPB prime volumes for pediatric cardiac operations have been reduced substantially in 
recent years. Up to 6 kg body weight, a Dideco Liliput oxygenator is now used with a 
total prime volume of 350 mL, including the ultrafilter and extra tubing needed for 
MUF. In the group of patients with a body weight of 6 to 14 kg, a Dideco 701 oxygenator 
is used with a total CPB prime volume of 650 mL, and in the group of patients with a 
body weight of 14 to 29 kg, a Dideco 702 is used with a total CPB prime volume of 750 
mL.
We studied retrospectively two comparable cohorts of patients and found significantly 
lower blood transfusion requirements and chest drain blood loss after MUF. Our 
perioperative protocols did not change during the period of the study. We believe that 
despite the shortcoming of not being prospective and randomized, this study clearly 
demonstrates the beneficial effects of MUF in a pediatric cardiac operative population. 
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circuit to the patient. The need for blood transfusion decreases significantly, as does 
postoperative blood loss. 
In many patients, mean blood pressures increased during MUF. This has also been 
observed by others [4, 5]. The rise in blood viscosity due to water loss may be 
responsible for this blood pressure increase. Another explanation may be found in the 
removal of vasoreactive substances by MUF. Inflammatory mediators such as 
interleukins, tumor necrosis factor, and activated complement components, many of them 
having cardiodepressive characteristics, are reported to be removed by ultrafiltration [6, 
7].
We did not measure total body water content, but others have reported significant 
decreases in total body water using MUF [5]. The problem of excess water is especially 
important after neonatal cardiac procedures. In the pre-MUF period (before July 1993), 
we observed this problem much more often than in the patients in whom MUF was used 
(after July 1993). 
Modified ultrafiltration is a useful tool to combat water retention after pediatric cardiac 
operations. It diminishes the need for blood transfusion by both removing excess water 
and returning all CPB blood to the patient in a concentrated form. It also decreases 
postoperative chest drain loss. Of course, the use of MUF does not reduce the need for 
further efforts to limit the CPB prime volume to diminish water overload while at the 
same time trying to restrict the use of blood and blood products as much as possible. Our 
CPB prime volumes for pediatric cardiac operations have been reduced substantially in 
recent years. Up to 6 kg body weight, a Dideco Liliput oxygenator is now used with a 
total prime volume of 350 mL, including the ultrafilter and extra tubing needed for 
MUF. In the group of patients with a body weight of 6 to 14 kg, a Dideco 701 oxygenator 
is used with a total CPB prime volume of 650 mL, and in the group of patients with a 
body weight of 14 to 29 kg, a Dideco 702 is used with a total CPB prime volume of 750 
mL.
We studied retrospectively two comparable cohorts of patients and found significantly 
lower blood transfusion requirements and chest drain blood loss after MUF. Our 
perioperative protocols did not change during the period of the study. We believe that 
despite the shortcoming of not being prospective and randomized, this study clearly 
demonstrates the beneficial effects of MUF in a pediatric cardiac operative population. 
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Abstract
Background. Oxidative damage and inflammation are believed to play an important role 
in postoperative complications after cardiopulmonary bypass. During bypass, a prime 
solution with a high antioxidant capacity may reduce the oxidative damage and 
inflammation. We investigated total antioxidant capacity and individual scavengers 
during the preparation of 2 different prime solutions. 
Methods. The prime solutions were prepared with either pasteurized human albumin 
or fresh frozen plasma. The total antioxidant capacity was measured with the total radical 
antioxidant parameter assay and with the ferric-reducing ability of plasma assay. The 
individual scavengers vitamin C, sulfhydryl groups, uric acid, and total protein were 
measured before, during, and after the prime preparation. Malondialdehyde was 
measured as a parameter for lipid peroxidation. 
Results. Neither prime solution showed a total radical antioxidant parameter value. The 
ferric-reducing ability of plasma value of prime solutions was lower than that of 
undiluted human albumin or fresh frozen plasma. Addition of mannitol did not increase 
the ferric-reducing ability of plasma value. Vitamin C was only found in the fresh frozen 
plasma prime. Both prime solutions contained sulfhydryl groups and uric acid in low 
concentrations. During ultrafiltration, low-molecular-weight antioxidants were lost into 
the ultrafiltrate. 
Conclusions. We showed that prime solutions based on either albumin or fresh frozen 
plasma had very low antioxidant capacity and that ultrafiltration of the prime solution 
further lowers this capacity. A prime solution with a low antioxidant capacity may 
increase oxidative stress in neonates undergoing cardiopulmonary bypass.
Introduction 
Oxidative damage and inflammation are believed to be important causes of morbidity 
related to cardiopulmonary bypass (CPB), which is high, especially in small infants [1]. 
During CPB, prooxidative substances, such as nonprotein-bound iron, are released while 
the plasma antioxidant capacity decreases, resulting in excess accumulation of reactive 
oxygen species [2]. This may be especially important in neonates who, compared with 
more mature patients, already have low plasma iron-binding capacity and poor 
antioxidant defenses, which decrease even further after CPB [3, 4]. This may cause 
oxidative stress, direct tissue damage, and multiorgan failure. Moreover, oxidative stress 
may upregulate the inflammatory response and initiate a vicious oxidative circle [1, 5].
Enhancing the antioxidant capacity of patients during CPB could limit the direct 
oxidative tissue damage and modulate the undesired inflammatory response.  
The prime solution of the CPB system can substantially affect the plasma antioxidant 
capacity because of the high ratio between prime and circulating volume of neonatal 
patients. As previously reported, even transfusion of a relatively small volume of fluid 
with a low antioxidant capacity decreases the ability of plasma of neonates to catabolize 
reactive oxygen species [6]. Thus, a large prime volume with a low antioxidant capacity 
may dramatically decrease the antioxidant capacity of neonates undergoing CPB. On the 
other hand, a supplementation of the prime solution with antioxidants could decrease the 
negative effect of the dilution and limit the oxidative stress during CPB [7-9]. Albumin-
based prime solution, which is routinely used in our institution, may have a lower 
antioxidant capacity than an alternative prime solution based on fresh frozen plasma 
(FFP). Ultrafiltration during prime preparation could change the antioxidant status of 
prime solution by means of removal of water-soluble antioxidants or prooxidative 
substances, such as nonprotein-bound iron. Therefore, we investigated the total 
antioxidant capacity, as well as that of selected individual antioxidants, during the 
preparation of these two different prime solutions. 
Materials and Methods 
This in vitro study was approved by the Scientific Committees of the Department of 
Pediatrics and the Department of Thoracic Surgery. Preserved packed red blood cells 
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(RBCs; stored for <5 days) and FFP were delivered by our blood bank. RBCs were 
preserved and stored in saline, adenosine, glucose, and mannitol (SAGM) solution. FFP 
contains citrate, which is used as an anticoagulant during donor blood preparation. 
Informed consent of the donors was obtained. Twenty percent human albumin solution 
was obtained from CLB (Amsterdam, The Netherlands). This is a plasma-derived product 
prepared by means of ethanol fractionation and pasteurization (10 hours at 60°C). It 
contains mainly albumin (95%), but other proteins are also present, such as prealbumin 
and haptoglobin. 
Prime Composition and Preparation 
Prime composition and preparation are shown in Figure 1. Two different prime solutions 
on the basis of either albumin or FFP were prepared, each on 5 separate occasions.
Figure 1. Composition, preparation, and sampling of the primes. 1, Clear prime; 2, RBC prime before 
ultrafiltration; 3, RBC prime after ultrafiltration; 4, RBC prime after mannitol and bicarbonate; 5, 6, and 7,
RBC prime after 20, 40, and 60 minutes, respectively, at a temperature of 32°C. Sample of ultrafiltrate was 
collected at the end of ultrafiltration. 
At room temperature, the cardiotomy reservoir of a Dideco Lilliput 901 CPB system 
(Dideco, Mirandola, Italy) was filled with 500 mL of Ringer’s solution with 1500 IU of 
heparin and either 100 mL of 20% human albumin (ALB prime) or 100 mL of FFP (FFP 
prime). The oxygenator was filled, and after 15 minutes of circulation, 100 mL of 
packed RBCs were added to the clear ALB or FFP prime. After 5 minutes of circulation 
of this RBC prime, ultrafiltration was performed with a Minntech Hemocor HPH 400 
(Minntech Corp, Minneapolis, Minn) to reduce the prime volume to 350 mL. Then 1.0 g 
of mannitol and 4.0 mL of 8.4% sodium bicarbonate were added. Five minutes later, the 
temperature of the prime was increased to 32°C for 60 minutes. (In a clinical situation, 
this decreases the temperature difference between prime and patient.) The flow of the 
prime and the air flow (fraction of inspired oxygen = 0.21) was 0.50 L/min. The flow 
through the ultrafilter was 0.20 L/min, with a constant pressure of 75 mmHg. 
Samples
Samples of undiluted albumin solution and FFP were collected. Samples (3 mL) of the 
prime at various stages of its preparation and one sample of ultrafiltrate were collected, 
protected from light, immediately cooled, and transported to the laboratory to be 
centrifuged (4°C for 5 minutes at 2000 rpm). For measurements of vitamin C, the 
samples were stabilized with metaphosphoric acid and deferoxamine mesylate (Desferal). 
The samples were frozen until analysis (–80°C under argon). Preliminary studies showed 
that values did not change during storage [3]. 
Laboratory Measurements 
The total antioxidant capacity was measured with two different methods. The total radical 
antioxidant parameter (TRAP) assay measures the ability of the investigated sample to 
inhibit peroxidation of the target lipid (linoleic acid) induced by peroxyl radicals. This 
lipid peroxidation is measured by means of oxygen consumption with an oxygen  
electrode. Extent of the inhibition, if any, is quantified by using Trolox (water-soluble 
analog of vitamin E) as a calibrator [6, 10]. The ferric-reducing ability of plasma (FRAP) 
assay measures the capacity of the sample to reduce ferric ion (Fe3+) to the ferrous form 
(Fe2+). This reduction can be measured by means of spectrophotometry because ferrous 
ions bind to tripyridyltriazin to form a blue-colored complex. The results of the assay are 
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quantitated by use of a solution containing ferrous ions in a known concentration as a 
calibrator [11].
Individual Antioxidants 
Vitamin C was measured with high-performance liquid chromatography, as previously 
described [12-14]. This method measures total ascorbic acid and its oxidized form, and 
reduced ascorbic acid is calculated by subtraction. Knowing the concentration of vitamin 
C and the exact (corrected for sampling) volume of prime, we calculated the total amount 
of vitamin C in the prime. Sulfhydryl groups were determined by spectrophotometry, as 
previously described [15]. Uric acid, total protein, and albumin were measured by means 
of an automatic analyzer (Hitachi 747; Roche Diagnostics GMBH, Mannheim, 
Germany). 
Lipid Peroxidation Product 
Malonyldialdehyde (MDA) was measured by means of high-performance liquid 
chromatography, as adapted and modified from the previous study [16]. 
Statistics 
All results are reported as means ± standard deviation (SD). Differences between 
oxidized/total ratio of vitamin C before and after FFP prime preparation were tested by 
using the t test for paired samples. Differences between means of the amount of vitamin 
C present in the prime in different samples were measured by 1-way analysis of variance. 
Differences between the amount of vitamin C present in FFP prime before and after 
ultrafiltration were tested by using a paired t test. Correlation between free 
hemoglobin/heme concentration and oxidized/total vitamin C ratio was tested with the 
Pearson method by the 2-tailed test of significance. 
Results
The samples from one FFP prime preparation became hemolytic during centrifugation. 
After box-plot analysis, we excluded the results of these samples from FRAP and vitamin 
C statistic analysis. 
Total Antioxidant Capacity 
ALB prime. The TRAP assay detected no antioxidant capacity in either undiluted 
albumin solution or in the samples of the prime. The FRAP value in the undiluted 
albumin solution was 1813.7 mol/L. In the clear prime, the FRAP value was 651.6 ± 
190.8 mol/L and increased during the procedure, reaching a value of 901.2 ± 255.9 
mol/L. The ultrafiltrate had a FRAP value of 542.5 ± 225.3 mol/L (Figure 2). 
Figure 2. Measurement of FRAP assay (mean ± SD; circulation 6 excluded). Sampling is described in the 
legend for Figure 1. UF, Ultrafiltration. 
FFP prime. The TRAP value of undiluted FFP was 752.75 ± 40.1 mol/L; however, the 
assay detected no antioxidant capacity in the samples of the prime. The FRAP value in 
the undiluted FFP was 2841.5 ± 703.2 mol/L. In the clear prime the FRAP value was 
486.9 ± 49.8 mol/L and increased during the procedure, reaching a value of 635.3 ± 
36.4 mol/L. The ultrafiltrate had a FRAP value of 472.1 ± 17.4 mol/L (Figure 2). 
Although there was a difference in FRAP values between the ALB and the FFP 
primes after the preparation, this difference was not significant (P = .08). 
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Vitamin C 
ALB prime. No vitamin C was detected. 
FFP prime. FFP prime contained vitamin C (Figure 3,A-C). Its mean concentration in the 
clear prime was 8.86 ± 3.15 mol/L, ranging from 6.07 to 11.80 mol/L and decreasing 
to 4.64 ± 1.27 mol/L after 20 minutes of circulation of the prime at 32°C and to 2.78 ± 
0.37 mol/L after completion of the procedure (analysis of variance, P = .0035).
Figure 3. A, Individual vitamin C 
concentrations (in micromoles per 
liter) during the preparation of FFP 
prime (circulation 6 excluded). 
Sampling is described in the legend 
for Figure 1. Notice the large 
variability in concentrations between 
the different circulations (CIR) and
especially the concentrations in the 
ultrafiltrates (UF). B, The total load 
(mean) of vitamin C in milligrams 
during the preparation of the FFP 
primes (circulation 6 excluded). 
Sampling is described in the legend 
for Figure 1. Notice the loss of vitamin 
C during the whole preparation (paired 
t test: P = .017 for sample 1 and 
sample 7; before and after the 
preparation, respectively) and 
especially during ultrafiltration (paired 
t test: P = .019 for sample 2 and 
sample 3; before and after 
ultrafiltration, respectively). C, 
Measurements of oxidized/total ratio 
vitamin C (circulation 6 excluded). 
Sampling is described in the legend 
for Figure 1 (paired t test: P = .006 for 
sample 1 and sample 7). 
In the ultrafiltrates, vitamin C was found in the same concentration as in the primes. 
Because of this, the total amount of vitamin C in the prime decreased during 
ultrafiltration from 1.04 ± 0.40 mg to 0.57 ± 0.20 mg. During the circulation of the prime 
at 32°C, the total amount of vitamin C decreased even further to 0.18 ± 0.03 mg after 
completion of the procedure. The oxidized/total vitamin C ratio increased from 0.11 ± 
0.07 in the clear prime to 0.17 ± 0.04 after completion of the procedure. The ratio was 
positively correlated with free hemoglobin/heme concentrations in the primes (r = 0.88-
0.83 and 0.83-0.69, respectively). Interestingly, in the hemolytic samples the ratio 
increased to 0.49 after the preparation and was strongly correlated with concentrations of 
heme (r = 0.89 and P = .003, data not shown). 
Sulfhydryl Groups 
Sulfyhdryl data are shown in Figure 4. 
ALB prime. Clear prime contained sulfhydryl groups at a concentration of 203.4 ± 0.9 
mol/L. This concentration did not change after addition of RBCs but increased after 
ultrafiltration to 315.8 ± 10.9 mol/L and remained stable until completion of the 
preparation. Ultrafiltrate contained no sulfhydryl group. Calculated sulfhydryl/total 
protein ratio was 4.74 ± 0.20 in clear prime and 5.53 ± 0.77 after completion of prime 
preparation.
Figure 4. Measurements of 
sulfhydryl (SH) groups (mean ± 
SD). Sampling is described in the 
legend for Figure 1. No 
sulfhydryl groups were present in 
the ultrafiltrate. 
FFP prime. Clear prime contained sulfhydryl groups at a concentration of 70.1 ± 12.2 
mol/L. This concentration did not change after adding RBCs but increased slightly 
after ultrafiltration to 111.8 ± 15.2 mol/L and remained stable until completion of the 
preparation. The ultrafiltrate contained no sulfhydryl group. Calculated sulfhydryl/total 
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vitamin C (circulation 6 excluded). 
Sampling is described in the legend 
for Figure 1 (paired t test: P = .006 for 
sample 1 and sample 7). 
In the ultrafiltrates, vitamin C was found in the same concentration as in the primes. 
Because of this, the total amount of vitamin C in the prime decreased during 
ultrafiltration from 1.04 ± 0.40 mg to 0.57 ± 0.20 mg. During the circulation of the prime 
at 32°C, the total amount of vitamin C decreased even further to 0.18 ± 0.03 mg after 
completion of the procedure. The oxidized/total vitamin C ratio increased from 0.11 ± 
0.07 in the clear prime to 0.17 ± 0.04 after completion of the procedure. The ratio was 
positively correlated with free hemoglobin/heme concentrations in the primes (r = 0.88-
0.83 and 0.83-0.69, respectively). Interestingly, in the hemolytic samples the ratio 
increased to 0.49 after the preparation and was strongly correlated with concentrations of 
heme (r = 0.89 and P = .003, data not shown). 
Sulfhydryl Groups 
Sulfyhdryl data are shown in Figure 4. 
ALB prime. Clear prime contained sulfhydryl groups at a concentration of 203.4 ± 0.9 
mol/L. This concentration did not change after addition of RBCs but increased after 
ultrafiltration to 315.8 ± 10.9 mol/L and remained stable until completion of the 
preparation. Ultrafiltrate contained no sulfhydryl group. Calculated sulfhydryl/total 
protein ratio was 4.74 ± 0.20 in clear prime and 5.53 ± 0.77 after completion of prime 
preparation.
Figure 4. Measurements of 
sulfhydryl (SH) groups (mean ± 
SD). Sampling is described in the 
legend for Figure 1. No 
sulfhydryl groups were present in 
the ultrafiltrate. 
FFP prime. Clear prime contained sulfhydryl groups at a concentration of 70.1 ± 12.2 
mol/L. This concentration did not change after adding RBCs but increased slightly 
after ultrafiltration to 111.8 ± 15.2 mol/L and remained stable until completion of the 
preparation. The ultrafiltrate contained no sulfhydryl group. Calculated sulfhydryl/total 




ALB prime. Clear prime contained no uric acid. After adding RBCs, uric acid was 
detectable at a concentration of 0.01 ± less than 0.001 mmol/L (mean ± SD) and 
increased to 0.02 ± 0.01 mmol/L at the end of preparation. In ultrafiltrate, uric acid was 
found at a concentration of 0.01 ± 0.01 mmol/L. 
FFP prime. Clear prime contained uric acid at a concentration of 0.04 ± less than 0.001 
mmol/L and remained stable until the temperature increased and then increased to 
0.06 ± 0.01 mmol/L after completion of prime preparation. In the ultrafiltrate, uric acid 
was found in the concentration of 0.04 ± less than 0.001 mmol/L. 
Total Protein and Albumin 
ALB prime. Clear prime contained 42 ± 1.8 g/L protein (consisting of albumin, although 
we did not exclude traces of other proteins). Addition of RBCs slightly decreased the 
concentration of protein, and ultrafiltration increased it to 62 ± 2 g/L. After that, the 
protein content remained stable. 
FFP prime. Clear prime contained 12 ± 0.9 g/L protein. Adding RBCs slightly decreased 
the concentration of protein, and ultrafiltration increased it to 18.4 ± 0.9 g/L. After that, 
the protein content remained stable. Protein in all FFP samples consisted of 55% to 60% 
albumin. 
Malonyldialdehyde 
ALB prime. Clear prime contained MDA at a concentration of 0.43 ± 0.05 mol/L. This 
concentration increased slightly after adding RBCs (0.47 ± 0.1 mol/L) and much more 
after ultrafiltration to 0.66 ± 0.08 mol/L and slightly decreased during circulation at 
32°C, reaching 0.62 ± 0.1 mol/L after completion of the preparation. The ultrafiltrate
contained MDA at a concentration of 0.13 ± 0.02 mol/L.  
FFP prime. Clear prime contained MDA at a concentration of 0.19 ± 0.07 mol/L. This 
concentration increased slightly after adding RBCs to 0.28 ± 0.02 mol/L and after 
ultrafiltration to 0.31 ± 0.05 mol/L and remained stable until completion of the 
preparation. Ultrafiltrate contained MDA at a concentration of 0.12 ± 0.04 mol/L. 
Discussion
CPB was reported to completely deplete the total antioxidant capacity in neonates [4]. 
However, a possible effect of the composition of prime solution and its dilution effect on 
plasma of patients was not discussed. In our experience, even transfusion of a relatively 
small volume of pasteurized plasma protein solution, a plasma-derived product with no 
TRAP value, can decrease the antioxidant capacity of plasma of neonates [6]. 
Table 1. Plasma concentrations of the various plasma antioxidants compared with the 
concentrations in the prime solutions after the prime preparation procedure 
Term babies  Adults   ALB prime  FFP prime 
Uric acid ( mol/L)   317 ± 66  285 ± 55  0.02 ± 0.01  0.06 ± 0.01 
Vitamin C ( mol/L)   130 ± 55  62 ± 16  ND   2.78 ± 0.37 
Sulfhydryl groups ( mol/L)  422 ± 80  496 ± 57  315.8 ± 10.9  111.8 ± 15.2 
Data are presented as means ± standard deviation. Data for term babies and adults are adapted from 
reference28. FFP, fresh frozen plasma; ND, not detectable. 
The ratio between the prime volume and the circulating volume of neonates is much 
higher than during transfusion. As a result, prime solution with a low antioxidant capacity 
could substantially decrease the ability of these patients to metabolize reactive oxygen 
species. We therefore studied the antioxidant capacity of two different prime solutions. 
We showed that both ALB and FFP prime solutions have a low total antioxidant capacity. 
TRAP assay revealed no antioxidant capacity in ALB prime, reflecting the fact that 
human albumin solution has no TRAP value. This is probably because of aggressive 
processing of donor plasma causing damage or loss of antioxidants during manufacturing 
of this plasma-derived product. The TRAP value of FFP prime was also undetectable, 
probably as a result of dilution of donor plasma, which had a normal TRAP value. The 
FRAP value of human albumin solution was originally much lower than that of FFP. 
However, the FRAP value of the clear ALB prime was, surprisingly, slightly higher than 
that of FFP prime. This suggests a different effect of dilution of human albumin solution 
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detectable at a concentration of 0.01 ± less than 0.001 mmol/L (mean ± SD) and 
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FFP prime. Clear prime contained uric acid at a concentration of 0.04 ± less than 0.001 
mmol/L and remained stable until the temperature increased and then increased to 
0.06 ± 0.01 mmol/L after completion of prime preparation. In the ultrafiltrate, uric acid 
was found in the concentration of 0.04 ± less than 0.001 mmol/L. 
Total Protein and Albumin 
ALB prime. Clear prime contained 42 ± 1.8 g/L protein (consisting of albumin, although 
we did not exclude traces of other proteins). Addition of RBCs slightly decreased the 
concentration of protein, and ultrafiltration increased it to 62 ± 2 g/L. After that, the 
protein content remained stable. 
FFP prime. Clear prime contained 12 ± 0.9 g/L protein. Adding RBCs slightly decreased 
the concentration of protein, and ultrafiltration increased it to 18.4 ± 0.9 g/L. After that, 
the protein content remained stable. Protein in all FFP samples consisted of 55% to 60% 
albumin. 
Malonyldialdehyde 
ALB prime. Clear prime contained MDA at a concentration of 0.43 ± 0.05 mol/L. This 
concentration increased slightly after adding RBCs (0.47 ± 0.1 mol/L) and much more 
after ultrafiltration to 0.66 ± 0.08 mol/L and slightly decreased during circulation at 
32°C, reaching 0.62 ± 0.1 mol/L after completion of the preparation. The ultrafiltrate
contained MDA at a concentration of 0.13 ± 0.02 mol/L.  
FFP prime. Clear prime contained MDA at a concentration of 0.19 ± 0.07 mol/L. This 
concentration increased slightly after adding RBCs to 0.28 ± 0.02 mol/L and after 
ultrafiltration to 0.31 ± 0.05 mol/L and remained stable until completion of the 
preparation. Ultrafiltrate contained MDA at a concentration of 0.12 ± 0.04 mol/L. 
Discussion
CPB was reported to completely deplete the total antioxidant capacity in neonates [4]. 
However, a possible effect of the composition of prime solution and its dilution effect on 
plasma of patients was not discussed. In our experience, even transfusion of a relatively 
small volume of pasteurized plasma protein solution, a plasma-derived product with no 
TRAP value, can decrease the antioxidant capacity of plasma of neonates [6]. 
Table 1. Plasma concentrations of the various plasma antioxidants compared with the 
concentrations in the prime solutions after the prime preparation procedure 
Term babies  Adults   ALB prime  FFP prime 
Uric acid ( mol/L)   317 ± 66  285 ± 55  0.02 ± 0.01  0.06 ± 0.01 
Vitamin C ( mol/L)   130 ± 55  62 ± 16  ND   2.78 ± 0.37 
Sulfhydryl groups ( mol/L)  422 ± 80  496 ± 57  315.8 ± 10.9  111.8 ± 15.2 
Data are presented as means ± standard deviation. Data for term babies and adults are adapted from 
reference28. FFP, fresh frozen plasma; ND, not detectable. 
The ratio between the prime volume and the circulating volume of neonates is much 
higher than during transfusion. As a result, prime solution with a low antioxidant capacity 
could substantially decrease the ability of these patients to metabolize reactive oxygen 
species. We therefore studied the antioxidant capacity of two different prime solutions. 
We showed that both ALB and FFP prime solutions have a low total antioxidant capacity. 
TRAP assay revealed no antioxidant capacity in ALB prime, reflecting the fact that 
human albumin solution has no TRAP value. This is probably because of aggressive 
processing of donor plasma causing damage or loss of antioxidants during manufacturing 
of this plasma-derived product. The TRAP value of FFP prime was also undetectable, 
probably as a result of dilution of donor plasma, which had a normal TRAP value. The 
FRAP value of human albumin solution was originally much lower than that of FFP. 
However, the FRAP value of the clear ALB prime was, surprisingly, slightly higher than 
that of FFP prime. This suggests a different effect of dilution of human albumin solution 
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and FFP or an interaction with heparin. Heparin is believed to have an antioxidant 
activity; however, its exact mechanism is not clear [17]. Moreover, measurement of total 
antioxidant capacity can be influenced by heparinization of samples, giving higher 
apparent results [18]. In FFP prime this effect of heparin can be lower because of its 
binding to antithrombin III in donor plasma. In ALB prime, unbound heparin can 
possibly increase the results of the FRAP assay. Relatively high FRAP values of 
ultrafiltrates of both primes suggest that this assay mainly measures the effect of low-
molecular-weight antioxidants. Interestingly, the hemolytic samples had very high FRAP 
values. Mannitol, which is widely used as an important hydroxyl radical scavenger, did 
not improve the total antioxidant capacity of the prime solutions [19,20]. 
For further insight into the antioxidant properties of the prime solutions, we also 
investigated a few selected antioxidants during the prime preparation. Vitamin C, an 
important secondary antioxidant, was not detected in ALB prime, probably because of its 
loss during the production process of albumin solution. There was a large variability in 
vitamin C concentrations between the different preparations of the FFP prime, probably 
because of donor variability. These differences became small after the prime preparation. 
The concentrations remained stable after adding RBCs, bicarbonate, and mannitol but 
decreased sharply during circulation at 32°C. RBCs rapidly take up oxidized vitamin C 
and slowly release the reduced form of vitamin C [21]. This active uptake of vitamin C 
may explain the decrease of concentration of total vitamin C. Concomitantly, with a 
decreasing concentration of vitamin C, its oxidized/total ratio increased, suggesting a rise 
in oxidation or less effective recycling of oxidized vitamin C. Oxidation of vitamin C can 
be explained by interaction with pro-oxidative free hemoglobin/ heme present in the 
prime. Glutathione plays a crucial role in the recycling of oxidized vitamin C [22]. The 
ability of RBCs to maintain glutathione is diminished during the prime preparation 
(unpublished data). This can result in decreased recycling of vitamin C and increasing of 
its oxidized/total ratio in the prime solution. Ultrafiltration did not change the 
concentration of vitamin C; however, its total amount in the prime decreased because of 
loss into the ultrafiltrate.  
Uric acid is the most important antioxidant and contributor to the TRAP value of human 
plasma [6, 10]. Both primes contained very low concentrations of uric acid. However, it 
was much higher in FFP prime than in ALB prime. Uric acid in FFP prime originated 
from donor plasma, and its low concentration is an effect of its dilution. Clear ALB prime 
contained no uric acid, and RBCs added to the prime contributed to its minimal 
concentration thereafter. The concentration of uric acid in ultrafiltrate was the same as in 
the primes, indicating that this small molecule was (similarly to vitamin C) freely filtered 
out during ultrafiltration.
Proteins used to maintain the colloid osmotic pressure during CPB (especially albumin) 
can contribute to the antioxidant capacity of the primes. Albumin binds pro-oxidative  
heme and transition metals, whereas its sulfhydryl and, as recently reported, hydroxyl 
groups can act secondarily (eg, scavengers and antioxidants) [23, 24]. Moreover, human 
albumin solution also contains some haptoglobin, which binds potentially pro-oxidative 
hemoglobin [25]. ALB prime has higher protein (albumin) contents than FFP prime, 
which is a logical consequence of their composition. High albumin concentration in ALB 
prime could improve its antioxidant capacity [23]. Plasma sulfhydryl groups are mainly 
present in the cysteine components of proteins and in low concentrations in glutathione. 
However, the sulfhydryl/protein ratio was lower in ALB prime than in FFP prime, and we 
found free heme and nonprotein-bound iron in ALB prime (unpublished data). This can 
be explained by oxidation of sulfhydryl groups as a result of plasma processing during 
the production of albumin solution.  
MDA is a product of lipid peroxidation but can also attack proteins and DNA [26]. It was 
present in both clear primes in very low concentrations because of the effect of dilution 
of donor plasma and albumin solution. Concentrations of MDA in ultrafiltrate were much 
lower than in the primes, indicating that MDA, despite its small molecular size, was not 
effectively ultrafiltered. MDA can bind to proteins, which probably prevents its 
ultrafiltration.  
We saw hemolysis during centrifugation in the samples from FFP prime. Interestingly, 
when the same RBCs were used for ALB prime, no hemolysis was seen. It is possible 
that these particular RBCs were more susceptible for factors that could be stronger in FFP 
prime than in ALB prime. No TRAP value, lower FRAP value, the presence of vitamin 
C, a lower concentration of protein/albumin, and sulfhydryl groups in the FFP prime can 
be explanations for the hemolysis.  
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and FFP or an interaction with heparin. Heparin is believed to have an antioxidant 
activity; however, its exact mechanism is not clear [17]. Moreover, measurement of total 
antioxidant capacity can be influenced by heparinization of samples, giving higher 
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in oxidation or less effective recycling of oxidized vitamin C. Oxidation of vitamin C can 
be explained by interaction with pro-oxidative free hemoglobin/ heme present in the 
prime. Glutathione plays a crucial role in the recycling of oxidized vitamin C [22]. The 
ability of RBCs to maintain glutathione is diminished during the prime preparation 
(unpublished data). This can result in decreased recycling of vitamin C and increasing of 
its oxidized/total ratio in the prime solution. Ultrafiltration did not change the 
concentration of vitamin C; however, its total amount in the prime decreased because of 
loss into the ultrafiltrate.  
Uric acid is the most important antioxidant and contributor to the TRAP value of human 
plasma [6, 10]. Both primes contained very low concentrations of uric acid. However, it 
was much higher in FFP prime than in ALB prime. Uric acid in FFP prime originated 
from donor plasma, and its low concentration is an effect of its dilution. Clear ALB prime 
contained no uric acid, and RBCs added to the prime contributed to its minimal 
concentration thereafter. The concentration of uric acid in ultrafiltrate was the same as in 
the primes, indicating that this small molecule was (similarly to vitamin C) freely filtered 
out during ultrafiltration.
Proteins used to maintain the colloid osmotic pressure during CPB (especially albumin) 
can contribute to the antioxidant capacity of the primes. Albumin binds pro-oxidative  
heme and transition metals, whereas its sulfhydryl and, as recently reported, hydroxyl 
groups can act secondarily (eg, scavengers and antioxidants) [23, 24]. Moreover, human 
albumin solution also contains some haptoglobin, which binds potentially pro-oxidative 
hemoglobin [25]. ALB prime has higher protein (albumin) contents than FFP prime, 
which is a logical consequence of their composition. High albumin concentration in ALB 
prime could improve its antioxidant capacity [23]. Plasma sulfhydryl groups are mainly 
present in the cysteine components of proteins and in low concentrations in glutathione. 
However, the sulfhydryl/protein ratio was lower in ALB prime than in FFP prime, and we 
found free heme and nonprotein-bound iron in ALB prime (unpublished data). This can 
be explained by oxidation of sulfhydryl groups as a result of plasma processing during 
the production of albumin solution.  
MDA is a product of lipid peroxidation but can also attack proteins and DNA [26]. It was 
present in both clear primes in very low concentrations because of the effect of dilution 
of donor plasma and albumin solution. Concentrations of MDA in ultrafiltrate were much 
lower than in the primes, indicating that MDA, despite its small molecular size, was not 
effectively ultrafiltered. MDA can bind to proteins, which probably prevents its 
ultrafiltration.  
We saw hemolysis during centrifugation in the samples from FFP prime. Interestingly, 
when the same RBCs were used for ALB prime, no hemolysis was seen. It is possible 
that these particular RBCs were more susceptible for factors that could be stronger in FFP 
prime than in ALB prime. No TRAP value, lower FRAP value, the presence of vitamin 
C, a lower concentration of protein/albumin, and sulfhydryl groups in the FFP prime can 
be explanations for the hemolysis.  
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We used ultrafiltration during the preparation of the primes in an attempt to decrease the 
metabolic load from preserved RBCs and to reduce the prime volume [27]. In this study 
we showed that ultrafiltration also removes important low-molecular-weight antioxidants, 
such as vitamin C and uric acid. Their concentrations were not changed; however, the 
total amount of these antioxidants in the prime decreases. This implies that ultrafiltration 
during and after CPB may reduce the amount of important low-molecular-weight 
antioxidants in the circulation of the patient. However, we showed that despite the loss of 
these low-molecular-weight antioxidants, the total antioxidant capacity of the prime is 
not decreased after ultrafiltration. 
In conclusion, we showed that both ALB prime and FFP prime had no TRAP value. 
FRAP values were much lower than the values measured in the undiluted human albumin 
solution or in FFP prime. Mannitol did not improve the antioxidant capacity of the 
primes. During ultrafiltration, low-molecular-weight antioxidants were lost into the 
ultrafiltrate. Ultrafiltration was not able to decrease the concentration of MDA in the 
primes. Composition and antioxidant capacity of prime may substantially affect  
antioxidant capacity of neonates undergoing CPB. To emphasize the marked dilutional 
changes in antioxidant concentration that could occur, we compare the normal plasma 
antioxidant concentrations in terms of babies and adults with the concentrations 
found in prepared primes (Table 1) [28]. If ultrafiltration is used during the prime 
preparation, attention has to be paid to supplementation of antioxidants to the prime after 
the use of ultrafiltration.
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Background. Inflammation and oxidative damage are believed to play an important role 
in the postoperative complications after cardiopulmonary bypass (CPB) in neonates. 
During the preparation of the prime, red blood cells (RBCs) release non-protein-bound 
iron (NPBI) and free haemoglobin/haem (Hb/haem). The presence of these prooxidants in 
the prime solution may increase oxidative stress in neonates undergoing CPB. The 
solution used as the basis of the prime solution may influence the degree of this oxidative 
stress.
Methods. We investigated the NPBI and the Hb/haem binding capacities of two different 
prime solutions: a prime based on pasteurized human albumin and a prime based on fresh 
frozen plasma. The presence of NPBI and free Hb/haem were measured during and after 
the preparation of the prime solution.  
Results. Only in the albumin prime was NPBI detectable. However, in both primes, the 
concentrations of free Hb/haem increased.  
Conclusion. Thus, to reduce the prooxidative effects of NPBI and free Hb/haem, RBCs 
should be added to the prime at the last possible moment. Adding fresh frozen plasma 
should be considered, as this would result in no detectable NPBI in the prime solution.  
Introduction 
It is well known that neonates have poor antioxidative and iron binding capacities 
compared with infants and adults [1]. Pyles and coworkers demonstrated that after 
cardiopulmonary bypass (CPB) in children, the antioxidant capacity is diminished [2]. 
Other studies showed that the iron binding capacity during and after CPB decreases due 
to the effect of haemodilution [3, 4]. Preserved red blood cells (RBCs) are often added to 
the CPB prime solution to reverse the effect of haemodilution. Shear stress during the 
prime procedure and during CPB may cause haemolysis of RBCs and non-protein-bound 
iron (NPBI), free haemoglobin and haem (Hb/haem) are released [5]. Mumby showed 
that, especially in neonates, an iron overload occurred [6]. NPBI is normally not present 
in plasma. The antioxidative proteins, ceruloplasmin and transferrin, respectively, oxidize 
and bind iron, thereby offering considerable protection against oxygen radicals generated 
by iron [7]. Iron, when reduced and not protein bound, acts as a prooxidant, converting 
hydrogen peroxide to the highly reactive hydroxyl radical [8, 9]. Also free Hb/haem acts 
as a prooxidant. Free Hb/haem is bound by haptoglobin and haemopexin. Free Hb/haem 
stimulates lipid peroxidation [10]. Haem induces the expression of adhesion molecules in 
vascular endothelial cells and can potentiate the oxidative damage of these endothelial 
cells, caused by activated leucocytes [11, 13]. The prime solution of the CPB system can 
substantially affect the plasma antioxidant capacity of neonatal patients because of the 
relatively high prime and circulating volume ratio in this age group. We have recently 
demonstrated in vitro that even transfusion of a relatively small volume of fluid with 
a low antioxidant capacity decreases the ability of plasma of neonates to catabolize 
reactive oxygen species [14]. 
We investigated the release of NPBI and Hb/haem during the preparation of the prime 
solution. We prepared the prime solutions using either pasteurized human albumin 
solution, as routinely used in our institution, or fresh frozen plasma (FFP). It has 
been reported that FFP, obtained from adult donors, has a higher iron binding capacity 
than human albumin solution [15]. 
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Materials and methods 
Five units of preserved, leukocyte-depleted packed RBCs, stored less than five days, as 
well as five units of FFP were delivered by our bloodbank (Sanquin, Leiden, The 
Netherlands). RBCs are preserved and stored in a solution consisting of saline, adenosine, 
glucose and mannitol (SAGM). FFP contains citrate, which is used as anticoagulant 
during donor blood preparation. Informed consent of the donors was obtained. Human 
albumin 20% Cealb® solution was obtained from CLB (Amsterdam, The Netherlands). 
This is a plasma-derived product prepared by ethanol fractionation and pasteurization (10 
hours at 608C). It contains mainly albumin (95%), but other proteins are also present, 
such as prealbumin and haptoglobin. 
Prime composition and preparation (Figure 1) 
The two different prime solutions, based on either albumin or FFP, were prepared on 10 
separate occasions, imitating the typical clinical procedure for preparing the prime for 
neonatal CPB used in our hospital. At room temperature, the cardiotomy reservoir of a 
Dideco Lilliput 901 cardiopulmonary bypass system (Dideco, Mirandola, Italy) was filled 
with 500 ml of Ringer’s solution, with 1500 IU of heparin and either 100 ml human 
albumin 20% (ALB prime) or 100 ml fresh frozen plasma (FFP prime). The oxygenator 
was filled and, after 15 min of circulation, 100 ml of packed RBCs were added to the 
‘clear’ ALB prime or FFP prime. After 5 min of circulation of this ‘RBC prime’, 
ultrafiltration was performed with a Minntech Hemocor HPH 400 (Minntech Corp., 
Minneapolis, MN, USA) to reduce prime volume to a minimum needed prime volume 
of 350 ml. Then, 1.0 g of mannitol and 4.0 ml of sodium bicarbonate 8.4% were added. 
Five min later, the temperature was increased to 328C for 60 min (in the clinical setting, 
we would increase the temperature of the prime to avoid a temperature difference 
between prime and patient). During the whole preparation, the flow of the prime and the 
air flow (FiO2 0.21) was 0.50 LPM. The flow through the ultrafilter was 0.20 LPM with 
a constant pressure of 75 mmHg. 
Figure 1. Composition, preparation and sampling of the primes. Samples of prime: 1. Clear prime; 2. RBC 
prime before ultra.ltration; 3. RBC prime after ultra.ltration; 4. RBC prime after mannitol and bicarbonate; 
5, 6 and 7. RBC prime after 20, 40 and 60 min at a temperature of 328C, respectively. Sample of 
ultrafiltrate (UF) was collected at the end of ultrafiltration.
Samples (Figure 1) 
Samples (3 ml) of the prime at various stages of its preparation and one sample of 
ultrafiltrate were collected, protected from light, immediately cooled, transported to the 
laboratory and centrifuged (40C, 5 min, 2000 rpm). The supernatant was frozen till 
analysis (-/800C, under argon). Preliminary studies showed that values did not change 
during storage [1].
Laboratory measurements 
The bleomycin assay was used to measure nonhaem NPBI, as has been described 
elsewhere [16]. In brief, the assay system contained DNA, bleomycin and the 
investigated sample. In the presence of ascorbate, bleomycin causes DNA degradation if 
NPBI is present in the sample. The extent of this degradation is proportional to the 
amount of free iron. The products of the DNA degradation form adducts with 
thiobarbituric acid, which were measured at 532 nm with a spectrophotometer (Perkin-
Elmer Corp., Norwalk, CT, USA). Haem iron does not participate in this reaction nor 
interfere with the test if its concentration is less than 46.5 mmol/L, i.e., if the sample is 
not visibly pink [17].
Free Hb/haem was measured as previously described [18]. Briefly, glacial acetic acid 
added to the sample breaks down free haemoglobin to haem, which accelerates oxidation 
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of tetramethylbenzidine (TMB) in the presence of hydrogen peroxide. This oxidation is 
proportional to the quantity of haem present in the sample. Oxidized TMB was measured 
at 600 nm. Transferrin and ceruloplasmin were measured in our routine clinical chemistry 
laboratory using the Hitachi 911 (Hitachi Ltd., Tokyo, Japan). 
Statistics 
All results are reported as mean value +/standard deviation (SD). Differences in NPBI 
and Hb/haem between prime solutions during and after the procedure (within ALB prime 
or FFP prime group) were tested using the paired Student’s t -test. A p value < /0.05 was 
considered significant. 
Results
NPBI (Figure 2a,b) 
NPBI levels were measured in the samples of clear prime, after completion of the 
preparation and also in the ultrafiltrate. The FFP prime contained no detectable NPBI at 
any time. In the ALB prime, NPBI was always detected and the concentrations increased 
after completion of the preparation (13.3 +/1.8 versus 26.0 +/8.6 mmol/L). The 
ultrafiltrate samples, obtained during the ultrafiltration of ALB prime, also contained 
NPBI (8.0 +/0.8 mmol/L). 
Figure 2. (a) Measurements of NPBI during preparation of 
two selected ALB primes. Sampling as described in Figure 
1. Notice measurements in samples of ultrafiltrate. (b) 
Individual measurements of NPBI in clear ALB primes 
(sample 1) versus the same ALB primes after the 
preparation (sample 7). Paired t -test: p =/0.019. 
Hb/haem (Figure 3a,b) 
Both clear primes contained free Hb/haem in micromolar concentrations. These 
concentrations increased after adding the preserved RBCs. During ultrafiltration, no 
Hb/haem was filtered out during ALB prime preparation and only a small amount 
during FFP prime preparation, resulting in an increase of the Hb/haem concentration. 
Circulation of both primes at 320C further increased free Hb/haem concentration. There 
was a correlation between Hb/haem and free iron in the ALB prime (r=/0.79, p<0.001).
Figure 3. (a) Individual measurements of free 
Hb/haem in clear primes (sample 1) and in 
primes after preparation (sample 7). Paired t - 
test: p =/0.004 for ALB prime and p = 0.021 for 
FFP prime. (b) Measurements of free Hb/haem 
(mean/SD) during preparation of ALB and FFP 
primes. Sampling as described in Figure 1. 
Notice measurements in samples of ultrafiltrate. 
Transferin and ceruloplasmin 
The concentrations of both transferrin and ceruloplasmin were below the detectable 
range.
Discussion
We showed that the ALB prime contained NPBI, whereas the FFP prime did not. The 
time course of changes in NPBI levels was very similar to that of free Hb/haem levels 
and there was a strong correlation between these measurements in the ALB prime. Both 
NPBI and free Hb/haem probably originated from RBCs as a result of haemolysis.  
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In the FFP prime, NPBI was not detected, which suggests that FFP binds NPBI by intact 
transferrin and ceruloplasmin activity [1]. This antioxidative activity was present despite 
the fact that the dilution of plasma in FFP prime resulted in the concentrations of both 
transferrin and ceruloplasmin being below the detectable range of our routine clinical 
chemistry laboratory. The concentration of NPBI in the ALB prime was high and may 
have a prooxidant effect [22]. NPBI converts hydrogen peroxide into a highly reactive 
hydroxyl radical, which can react with lipids, proteins or DNA. This oxidative damage 
is believed to play a role in the pathogenesis of many neonatal diseases [23]. Mumby and 
coworkers demonstrated that neonates especially showed an iron overload after CPB [6]. 
Also, the effect of severe iron loading of transferrin and the presence of NPBI in acute 
dysfunction of the right ventricle after repair of tetralogy of Fallot has been reported [4]. 
Both clear primes contained potentially prooxidative free Hb/haem in micromolar 
concentrations, which is probably related to the damage to the RBCs when they are 
initially separated from the plasma during the production of albumin and FFP. The 
concentration of free Hb/haem increased after adding RBCs, after ultrafiltration and 
during circulation at 320C, suggesting that the stressed haemolysing RBCs contributed to 
this increase. Since no free Hb/haem was filtered out in the ALB prime, and only in a 
small amount in the FFP prime, the concentration of free Hb/haem increased after 
ultrafiltration due to fluid removal. The absence of Hb/haem in the ultrafiltrate of the 
ALB prime can be explained by its binding to albumin [11]. This probably did not occur 
in the FFP prime because of its minimal haptoglobin and haemopexin levels and a much 
lower concentration of albumin. The haem concentration in the prime was low, but 
additional haem release due to haemolysis during and after CPB could result in a larger 
haem load [5]. Haem induces the expression of adhesion molecules in vascular 
endothelial cells and can potentiate their oxidative damage caused by activated 
leucocytes [12, 13]. This process may play a role in hyperactivation of leucocytes after 
CPB [19]. Haem also diminishes the structural stability of the membrane of RBCs 
undergoing shear stress [20]. This can further increase the release of prooxidative 
Hb/haem or NPBI during CPB [5]. On the other hand, after long-term exposure, haem 
upregulates expression of haem oxygenase enzyme (H0-1), which protects cells against 
oxidative stress [21]. We used ultrafiltration during the preparation of the primes in an 
attempt to decrease the metabolic load from preserved RBCs and to reduce the prime 
volume [24]. We studied the ability of ultrafiltration to remove prooxidants from the 
primes. The concentration of Hb/haem after ultrafiltration increased due to fluid removal. 
This mechanism may also have contributed to the increase in NPBI after ultrafiltration of 
the ALB prime since the concentration of NPBI was low in the ultrafiltrate. Another 
explanation of the increasing levels of Hb/haem and NPBI after ultrafiltration is the 
release of these prooxidants caused by shear stress-induced damage of RBCs during the 
ultrafiltration procedure.
In summary, this study showed that, during and after the prime preparation procedure, 
RBCs were a source of prooxidative NPBI and free Hb/haem, which were not filtered out 
during the ultrafiltration. FFP is able, even after strong dilution, to bind prooxidative iron, 
in contrast to albumin where NPBI remained detectable. In an attempt to reduce the 
prooxidative capacity of the prime solution, we suggest adding the fresh, stored RBCs 
just prior to bypass, as this will decrease the stress affecting RBCs during the preparation 
of the prime. An in vivo study should determine the advantage of the FFP prime results in 
less iron overload during and after CPB in neonates. 
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transferrin and ceruloplasmin being below the detectable range of our routine clinical 
chemistry laboratory. The concentration of NPBI in the ALB prime was high and may 
have a prooxidant effect [22]. NPBI converts hydrogen peroxide into a highly reactive 
hydroxyl radical, which can react with lipids, proteins or DNA. This oxidative damage 
is believed to play a role in the pathogenesis of many neonatal diseases [23]. Mumby and 
coworkers demonstrated that neonates especially showed an iron overload after CPB [6]. 
Also, the effect of severe iron loading of transferrin and the presence of NPBI in acute 
dysfunction of the right ventricle after repair of tetralogy of Fallot has been reported [4]. 
Both clear primes contained potentially prooxidative free Hb/haem in micromolar 
concentrations, which is probably related to the damage to the RBCs when they are 
initially separated from the plasma during the production of albumin and FFP. The 
concentration of free Hb/haem increased after adding RBCs, after ultrafiltration and 
during circulation at 320C, suggesting that the stressed haemolysing RBCs contributed to 
this increase. Since no free Hb/haem was filtered out in the ALB prime, and only in a 
small amount in the FFP prime, the concentration of free Hb/haem increased after 
ultrafiltration due to fluid removal. The absence of Hb/haem in the ultrafiltrate of the 
ALB prime can be explained by its binding to albumin [11]. This probably did not occur 
in the FFP prime because of its minimal haptoglobin and haemopexin levels and a much 
lower concentration of albumin. The haem concentration in the prime was low, but 
additional haem release due to haemolysis during and after CPB could result in a larger 
haem load [5]. Haem induces the expression of adhesion molecules in vascular 
endothelial cells and can potentiate their oxidative damage caused by activated 
leucocytes [12, 13]. This process may play a role in hyperactivation of leucocytes after 
CPB [19]. Haem also diminishes the structural stability of the membrane of RBCs 
undergoing shear stress [20]. This can further increase the release of prooxidative 
Hb/haem or NPBI during CPB [5]. On the other hand, after long-term exposure, haem 
upregulates expression of haem oxygenase enzyme (H0-1), which protects cells against 
oxidative stress [21]. We used ultrafiltration during the preparation of the primes in an 
attempt to decrease the metabolic load from preserved RBCs and to reduce the prime 
volume [24]. We studied the ability of ultrafiltration to remove prooxidants from the 
primes. The concentration of Hb/haem after ultrafiltration increased due to fluid removal. 
This mechanism may also have contributed to the increase in NPBI after ultrafiltration of 
the ALB prime since the concentration of NPBI was low in the ultrafiltrate. Another 
explanation of the increasing levels of Hb/haem and NPBI after ultrafiltration is the 
release of these prooxidants caused by shear stress-induced damage of RBCs during the 
ultrafiltration procedure.
In summary, this study showed that, during and after the prime preparation procedure, 
RBCs were a source of prooxidative NPBI and free Hb/haem, which were not filtered out 
during the ultrafiltration. FFP is able, even after strong dilution, to bind prooxidative iron, 
in contrast to albumin where NPBI remained detectable. In an attempt to reduce the 
prooxidative capacity of the prime solution, we suggest adding the fresh, stored RBCs 
just prior to bypass, as this will decrease the stress affecting RBCs during the preparation 
of the prime. An in vivo study should determine the advantage of the FFP prime results in 
less iron overload during and after CPB in neonates. 
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Abstract
Background. Contact of blood with the artificial surfaces of the cardiopulmonary bypass 
(CPB) system is considered to be a main cause of complement activation. Improving the 
biocompatibility of the system by reduction of contact activation of blood elements and 
thereby producing less inflammatory response is evidently desired, especially for 
neonates and infants who are more susceptible to the deleterious effects of CPB. A 
phosphorylcholine coating, PHISIO®, is designed to mimic the natural interfaces of 
blood. The aim of this study is to compare the influence of a phosphorylcholine-coated 
CPB system versus an uncoated CPB system on complement activation and clinical 
outcomes. 
Methods. In this prospective, randomized, blind, one center study, 28 neonates and 
infants with a bodyweight between 3 and 6 kg who were undergoing cardiopulmonary 
bypass were divided in two groups, the phosphorylcholine group and the control group. 
Thirteen patients were assigned to the phosphorylcholine group and 15 patients to the 
control group. Patients with Down syndrome, prematurity, cyanosis, or reoperation were 
excluded. Complement factor C3b/c, human neutrophil elastase (HNE), interleukin-6, 
and C-reactive protein were measured before, during, and after CPB. Duration of 
intensive care stay, ventilation time, highest body temperature, and inotropic medication 
were the clinical variables.  
Results. No significant differences were found between the groups for complement factor 
C3b/c, HNE, interleukin-6, or C-reactive protein during and after CPB. No clinical 
differences were observed between the groups.
Conclusions. Phosphorylcholine coating does not attenuate the complement activation 
during CPB in neonates and infants. 
Introduction 
Seghaye and colleagues reported that the fullterm neonate shows significant complement 
activation and leukocytes stimulation when undergoing cardiopulmonary bypass (CPB) 
[1]. Complement activation and leukocytes stimulation may result in postoperative organ 
dysfunction. Contact of blood with the nonbiologic surfaces of the CPB system has been 
designated as the main cause of complement activation. Improving the biocompatibility 
of CPB systems by means of less contact activation of blood elements and thereby less 
inflammatory response is evidently desirable [2]. 
A phosphorylcholine coating, PHISIO® (Dideco, Mirandola, Italy), is designed to mimic 
natural cellular surfaces and thereby to avoid recognition by the blood as foreign 
material. The outer cell surface is composed of predominantly phosphorylcholine polar 
groups that largely contribute to the nonthrombogenic properties exhibited by blood cells. 
Because of the hydrophilic character of the polar head group, there is less protein 
adsorption [3]. Furthermore, phosphorylcholine is a regular component of the outer cell 
membrane of all human cells [4]. In this prospective, randomized, blind, one-center 
study, we aimed to compare the effects of phosphorylcholine coating versus noncoating 
of the CPB systems on complement activation, its effect on leukocytes stimulation, and 
clinical outcomes in neonates and infants with a bodyweight between 3 and 6 kg. For this 
purpose, we measured C3b/c, a stable complement activation product, human neutrophil 
elastase (HNE), as a marker of neutrophils degranulation [1], the cytokine interleukin-6 
(IL-6), which is a good predictor of clinical outcome [5], and C-reactive protein (CRP), 
an acute phase protein, as a marker for inflammatory response. Clinical variables were 
intensive care unit stay, ventilation time, the highest body temperature in the first 24 
postoperative hours, and use of inotropic medication.  
CARDIOVASCULAR
Material and Methods 
Patients
Twenty-eight patients with a bodyweight between 3 and 6 kg who were undergoing 
surgical repair of their congenital heart defects with the use of CPB and moderate (28oC)
hypothermia were included in this prospective, randomized, blind study. The Medical and 
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Ethical Committee of our institution approved the study in January 2002. Written 
informed consent from parents or guardians was obtained for all patients. 
Patients were randomly assigned into the phosphorylcholine-coated group (PC group; n= 
13) or into the noncoated control group (NC group; n=15). Patients with Down 
syndrome, other syndromes or chromosomal abnormalities, prematurity, cyanosis 
(defined as oxygen saturation lower than 75%), use of circulatory arrest, and cardiac 
reoperation were excluded from this study. Postoperatively, inotropic support was used 
if necessary. No steroids, aprotinin, and other medication that might affect the 
inflammatory response were used throughout the study. 
Anesthesia 
All patients were premedicated with oral midazolam (0.5 mg/kg). Anesthesia was 
induced with sevoflurane and continued with midazolam (0.10 mg · kg-1 · h-1), 
sufentanil (0.04 ug · kg-1 · min-1), and pancuronium (0.15 mg/kg). 
Cardiopulmonary Bypass 
Before aortic cannulation, heparin (300 IU/kg) was given, and the activated clotting time 
was maintained above 480 seconds during CPB. For all patients, a Dideco Lilliput D901 
(Dideco, Mirandola, Italy) closed system was used, with the difference of the 
phosphorylcholine coating. The coating was from arterial canula to venous canula, from 
“tip to tip.” A Stockert roller pump (Stockert Instrumente GMBH, Munich, Germany) 
was used, inducing a nonpulsatile flow. The priming solution of 270 mL consisted of 
100 mL fresh frozen plasma, 50 mL 20%, w/v, human albumin (Sanquin, Amsterdam, 
Netherlands), Mannitol (0.5 g/kg), Ringers’ solution, and packed red blood cells if 
necessary to maintain a hematocrit of 25%. The CPB flow was maintained at 2.4 L · m-2.
min -1 at 370C and 1.6 L · m -2 · min-1 at 250C nasopharyngeal. The alpha-stat method was 
used for blood gas management. For myocardial protection, St Thomas cardioplegia 
solution was given and repeated every 30 minutes. Ultrafiltration, conventional or 
modified, was not used throughout the study. 
Samples
Samples of whole blood (2 mL) were collected in tubes containing 10 mmol/L 
ethylenediamine tetraacetic acid, 10 mmol/L benzamidine, and 100 mg/mL soy bean 
trypsin inhibitor, final concentrations. Sample moments were after induction of 
anesthesia but before sternotomy (baseline), 10 minutes after start of CPB, 5 minutes 
before end of CPB, and 15 minutes and 6 hours after protamine administration. Samples 
were centrifuged (3,000 rpm, 10 minutes) and stored at –700C until analysis. 
Laboratory Measurements 
Plasma levels of activated C3 were measured with enzyme-linked immunosorbent assay 
(ELISA) in which specific monoclonal antibody against a neoepitope on activated C3 
was used to catch the activation fragments, and biotinlayed polyclonal sheep antibodies 
against C3 to detect bound complement fragments [6]. As the assay does not discriminate 
between C3b, C3bi, or C3c, the activation products detected in the assay are further 
referred to as C3b/c. Results were expressed as nmol/L C3b/c, referring to an in-house 
standard with known levels of activation products. Elastase- 1-antitrypsin complexes 
were measured with an ELISA in which antielastase antibodies were coated onto an 
ELISA plate, and bound complexes detected with biotinylated monoclonal antibody 
against complexed- 1-antitrypsin. Purified human neutrophili elastase added to pooled 
plasma was used as a standard [6]. Results were expressed as ng/mL elastase (HNE). 
Interleukin 6 and CRP were measured with sandwich-type ELISAs (CLB; Department 
Immune Reagents, Amsterdam, Netherlands).  
Collection of Clinical Data 
Data on intensive care unit stay, ventilation time, highest body temperature in the first 24 
hours, and use of inotropic medication were collected in a retrograde fashion. 
Statistical Analyses 
Statistical analyses were performed using the statistical computing package SPSS12.01 
(SPSS, Chicago, Illinois). Patients’ data were compared with unpaired t test. Data 
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corresponding to cytokines values were not normally distributed. After logarithmic 
transformation of the raw data, we used repeated measures analysis of variance 
with the Greenhouse-Geisser correction to test for differences within the groups 
throughout the five time periods and between the two groups. Clinical data were also not 
normally distributed and were analyzed with the Mann-Whitney U test. Raw data 
are expressed as mean + SD values. All p values less than 0.05 were considered 
statistically significant.  
Results
There was no difference between the two groups in patients’ age (p=0.80) bodyweight 
(p=0.97), and diagnoses. The CPB time (p=0.60) and aortic cross clamp time (p=0.94) 
showed no differences between the groups (Table 1). Four patients in the PC group and 3 
patients in the NC group were preoperatively treated with prostaglandin E1 (PGE1). 
No deaths or major complications occurred in either group. 
Table 1. Demographic and CPB Data 
 PC group NC group  
 mean SD mean SD p value
Number of patients 13  15   
Demographic data      
    Age (days)a 79.4 84.6 87.5 80.4 0.80 
Body weight (kg)a   4.2   0.98   4.2   0.96 0.97 
Diagnosis      
   AVSD 0  3   
   VSD 5  2   
   TAPVC 1  2   
   Truncus arteriosis 0  1   
   TGA 5  5   
   TOF 0  1   
    DORV 1  1   
    ASD 1  0   
CPB data      
   CPB time (min)a 117.5 48.6 108.6 38.0 0.60 
   Clamp time (min)a   68.9 32.1   69.7 26.3 0.94 
a Values expressed as mean ASD = atrial septal defect; AVSD = atrioventricular septum defect; CPB = 
cardiopulmonary bypass; DORV = double outlet right ventricle; min = minutes; NC = noncoated control 
group; PC = phosphorylcholine-coated group; p value = student t test; TAPVC = totally abnormal 
pulmonary connection; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; VSD = 
ventricular septal defect. 
There was a significant rise in complement factor C3b/c for both groups, but there was no 
significant difference between the groups. The C3b/c increased rapidly in both groups 
after the start of CPB and reached the highest point after the protamine administration. 
Six hours after CPB, complement factor C3b/c values had almost returned to baseline in 
both groups (Table 2). The HNE peaked at the end of the CPB procedure. The values 
decreased rapidly and had almost returned to baseline after 6 hours. Also, for HNE, 
there was a significant time difference in the groups, but over time, both groups showed 
equal behavior (Table 2). Interleukin-6 started to increase slightly during CPB and rose 
rapidly after the CPB procedure and protamine administration. After 6 hours, IL-6 was 
still increased (Table 2).  
Table 2 laboratory measurement results 
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Fig 1. (A) Values of C-reactive protein (CRP), with patients 
who used preoperative prostaglandin E1 included for statistical 
analysis. (Solid line = with phosphorylcholine coating; dashed 
line = no coating.) (B) Values of C-reactive protein (CRP), with 
patients who used preoperative prostaglandin E1 excluded from 
statistical analysis. 
(Solid line = with phosphorylcholine coating; dashed line = no 
coating.)
The mean length of stay in the pediatric intensive care unit was not different between the 
two groups. Also ventilation time, body temperature, and inotropic dosage 
were not significantly different in both groups (Table 3). 
ULAR
Discussion
The present study was performed to compare the effects of CPB on the inflammatory 
response and clinical outcomes of a phosphorylcholine-coated CPB system versus 
an uncoated CPB system in pediatric patients with a bodyweight of 3 to 6 kg. We were 
not able to show any differences between the two groups. Yu and colleagues showed an 
improved biocompatibility during an in vitro study with reduced protein adsorption and 
complement activation [3]. The results during in vivo studies are controversial. De Somer 
and colleagues showed lower complement activation and a better preservation of platelets 
in a study with 10 patients [7]. Böning and coworkers demonstrated that 
phosphorylcholine coating or heparin coating of the CPB system used for pediatric 
surgery causes the same biologic effects [8]. They also demonstrated that the group with 
a larger prime volume shows higher values of IL-6 and higher tumor necrosis factor-
[8]. Horten and coworkers were not able to show any differences between a heparin-
coated system and an uncoated system with a study population of 200 patients [9]. 
Interestingly, Tárnok and colleagues demonstrated that children undergoing major 
cardiovascular surgery without CPB show almost the same complement activation as the 
children undergoing major cardiovascular surgery with the use of CPB [10]. These 
findings are also reported in adults [11, 12]. The inflammatory response after CPB is not 
only initiated by the artificial surface of the CPB system, although it is seen by many as 
being the main cause [13]. The response is also triggered by the gas-blood interfaces, 
ischemia-reperfusion injury, and other proinflammatory stimuli [10, 11]. The duration of 
the CPB procedure and the condition of the patient play roles in the extent of the 
inflammation after CPB [14]. It is also known that suction and retransfusion of 
mediastinal shed blood contribute to the inflammatory response [15]. In our study, 
suction and retransfusion was performed equally in both groups. The pediatric population 
is a widely spread population regarding to the differences in age, bodyweight, diagnoses, 
and syndromes. To achieve a homogeneous group of patients for this study, we used 
strong exclusion criteria. 
Radical oxygen species (ROS) activates nuclear factor- B (NF- B), which is an 
important protein in the regulation of the acute phase response of inflammation. 
Nuclear factor- B stimulates the production of, among others, IL-1, IL-6, and tumor 
necrosis factor-  [16]. Down syndrome is a genetic disorder associated with ROS, and 
patients with Down syndrome show a wide range of defects regarding either specific or 
nonspecific immunity [17, 18]. Body and blood values of cyanotic patients are severely 
affected by the chronic hypoxia, and uncontrolled reoxygenation is associated with ROS 
[19]. Circulatory arrest with deep hypothermia gives a higher postoperative leukocyte 
count, probably due to a higher -adrenergic stimulation [20]. Complement levels 
correlate with gestational age, particularly in the late prenatal period. Preterm infants 
have lower complement activity and complement component levels than full-term infants 
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[21]. Also, neutrophil counts are lower in preterm infants [22]. Patients indicated for 
reoperations were excluded because of the expected longer surgery time.  
In conclusion, phosphorylcholine coating does not attenuate the complement activation 
during CPB, nor does it have an influence on clinical outcomes. As mentioned above, the 
inflammation after CPB is not only triggered by the artificial surface but is dependent 
upon many factors. Coating alone will not affect the inflammation as desired. Other 
agents should be considered for this purpose, such as ultrafiltration during or after CPB 
and the use of corticosteroids and protease inhibitors. 
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Background: Corticosteroids are used in cardiac surgery to reduce  pro-inflammatory 
mediators in pediatric cardiac surgery. Information about the interaction between the 
phosphorylcholine coating and corticosteroids is lacking. Phosphorylcholine coating is 
designed to improve the biocompatibility of the cardiopulmonary bypass (CPB) system 
and thereby to attenuate the activation of blood elements and to reduce the inflammatory 
response.
Methods: In this in vitro study 20 separate CPB pump runs (4 groups) with and without 
dexamethasone and with and without coating were prepared. Measurements were done to 
compare the effects of adding dexamethasone to phosphorylcholine coated CPB systems 
versus uncoated systems with the use of whole blood. The  changes in concentration of 
dexamethasone itself in the two different systems were investigated and the production of 
the cytokines IL-6, IL-8 and IL-10 as well. 
Results: Changes in dexamethasone concentrations were significant throughout the study 
period within each group. Coating did not significantly affect dexamethasone distribution 
throughout the study. Dexamethasone was also found in the ultrafiltrate. No differences 
in interleukin production were found between the groups except for the group with 
coating without dexamethasone, IL-8 increased significantly in this group.
Conclusions: We showed that there is no interaction between dexamethasone and the 
phosphorylcholine coating. We also showed that coated CPB systems do not affect 
significantly the production of interleukins in an in vitro model of CPB except for IL-8 
which significantly increased in de coated group without dexamethasone. Our study 
confirms that an in vitro model is unable to trigger the production of IL-10.
Introduction 
The use of CPB is associated with a systemic inflammatory response that can lead to 
organ injury and postoperative morbidity.1 CPB is a potent stimulus for the release of 
pro-inflammatory cytokines including tumor necrosis factor alpha (TNF- ) and 
interleukin (IL) 1, 6 and 8. 
Corticosteroids have been used in cardiac surgery for the last 30 years. Dexamethasone is 
a long-acting glucocorticoid with powerful anti-inflammatory and immunosuppressive 
effects. Dexamethasone is increasingly used in cardiac surgery. Several groups have 
reported that steroids given before the start of CPB, reduce pro-inflammatory mediators 
in adult and pediatric cardiac surgery alike.2,3 Dexamethasone is strongly bound to 
proteins. No information exists about the effect of the pump prime and subsequent 
(modified) ultrafiltration on distribution and elimination of the free dexamethasone. 
There is also lack of information as to the interaction between the phosphorylcholine 
coating and dexamethasone. 
Improving the biocompatibility of CPB systems with a coating is believed to attenuate 
the activation of blood elements thereby decreasing the  inflammatory response. The 
phosphorylcholine coating PHISIO® (Dideco, Mirandola, Italy), is designed to mimic 
natural cellular surfaces. Phosphorylcholine is a regular component of the outer cell 
membrane of all human cells.4
In a previous study we have compared a phosphorylcholine coated cardiopulmonary 
bypass system to an uncoated system in pediatric patients undergoing cardiac surgery. 
The use of this coated system did not affect the parameters measured, such as C3b/c, 
Elastase HNE, Il-6 and CRP.5
The aims of the present in vitro study were twofold. First to measure the changes in 
concentration of dexamethasone in the two different systems, phosphorylcholine coated 
and uncoated CPB systems and due to the fact that the CPB system is not the only 




Background: Corticosteroids are used in cardiac surgery to reduce  pro-inflammatory 
mediators in pediatric cardiac surgery. Information about the interaction between the 
phosphorylcholine coating and corticosteroids is lacking. Phosphorylcholine coating is 
designed to improve the biocompatibility of the cardiopulmonary bypass (CPB) system 
and thereby to attenuate the activation of blood elements and to reduce the inflammatory 
response.
Methods: In this in vitro study 20 separate CPB pump runs (4 groups) with and without 
dexamethasone and with and without coating were prepared. Measurements were done to 
compare the effects of adding dexamethasone to phosphorylcholine coated CPB systems 
versus uncoated systems with the use of whole blood. The  changes in concentration of 
dexamethasone itself in the two different systems were investigated and the production of 
the cytokines IL-6, IL-8 and IL-10 as well. 
Results: Changes in dexamethasone concentrations were significant throughout the study 
period within each group. Coating did not significantly affect dexamethasone distribution 
throughout the study. Dexamethasone was also found in the ultrafiltrate. No differences 
in interleukin production were found between the groups except for the group with 
coating without dexamethasone, IL-8 increased significantly in this group.
Conclusions: We showed that there is no interaction between dexamethasone and the 
phosphorylcholine coating. We also showed that coated CPB systems do not affect 
significantly the production of interleukins in an in vitro model of CPB except for IL-8 
which significantly increased in de coated group without dexamethasone. Our study 
confirms that an in vitro model is unable to trigger the production of IL-10.
Introduction 
The use of CPB is associated with a systemic inflammatory response that can lead to 
organ injury and postoperative morbidity.1 CPB is a potent stimulus for the release of 
pro-inflammatory cytokines including tumor necrosis factor alpha (TNF- ) and 
interleukin (IL) 1, 6 and 8. 
Corticosteroids have been used in cardiac surgery for the last 30 years. Dexamethasone is 
a long-acting glucocorticoid with powerful anti-inflammatory and immunosuppressive 
effects. Dexamethasone is increasingly used in cardiac surgery. Several groups have 
reported that steroids given before the start of CPB, reduce pro-inflammatory mediators 
in adult and pediatric cardiac surgery alike.2,3 Dexamethasone is strongly bound to 
proteins. No information exists about the effect of the pump prime and subsequent 
(modified) ultrafiltration on distribution and elimination of the free dexamethasone. 
There is also lack of information as to the interaction between the phosphorylcholine 
coating and dexamethasone. 
Improving the biocompatibility of CPB systems with a coating is believed to attenuate 
the activation of blood elements thereby decreasing the  inflammatory response. The 
phosphorylcholine coating PHISIO® (Dideco, Mirandola, Italy), is designed to mimic 
natural cellular surfaces. Phosphorylcholine is a regular component of the outer cell 
membrane of all human cells.4
In a previous study we have compared a phosphorylcholine coated cardiopulmonary 
bypass system to an uncoated system in pediatric patients undergoing cardiac surgery. 
The use of this coated system did not affect the parameters measured, such as C3b/c, 
Elastase HNE, Il-6 and CRP.5
The aims of the present in vitro study were twofold. First to measure the changes in 
concentration of dexamethasone in the two different systems, phosphorylcholine coated 
and uncoated CPB systems and due to the fact that the CPB system is not the only 
activator of the inflammatory response we also measure inflammatory cytokines in both 
systems. 
74
Material and Methods 
Ten units of fresh whole blood were delivered by our blood bank (Sanquin, Leiden, The 
Netherlands) and used for 20 separate in vitro experimental circulations. Five hundred ml 
of whole blood was collected in a bag containing citrate-phosphate-dextrose (70 ml) as 
anticoagulant and cooled directly to 220C. Written informed consent of the blood donors 
was obtained. Every blood bag was used for 2 circulations (200 ml for each run), in an 
uncoated system and in a coated system. Four experimental circulation groups were 
studied, 5 uncoated systems without dexamethasone (UND), 5 coated systems without 
dexamethasone (CND), 5 uncoated systems with dexamethasone (UWD) and 5 coated 
systems with dexamethasone (CWD).  
Bypass system and prime procedure 
For all circulations a Dideco Lilliput D901® (Dideco, Mirandola, Italy) with integrated 
soft shell venous reservoir was used. The PHISIO® coated system were completely 
coated ‘from tip to tip’. A Stockert® SIII rollerpump (Stockert Instrumente Gmbh, 
Munich, Germany) was used inducing nonpulsatile flow. At the end of the circulation 
ultrafiltration was performed with a Jostra BC 20 plus® (Maquet CP, Hirrlingen, 
Germany) imitating modified ultrafiltration.  
All systems were primed with 100 ml 20% human albumin (Octapharma, Vienna, 
Austria) 200 ml Ringers’ solution, 5 ml 20% mannitol (Baxter BV NL, Utrecht, The 
Netherlands) and 1000 IE Heparin (LEO Pharma, Breda, The Netherlands) imitating the 
standard prime composition used in our institution. In the dexamethasone groups 5 mg 
dexamethasone (Pharmacy, Leiden University Medical Center (LUMC), The 
Netherlands) was added to the prime. Doses of mannitol and dexamethasone were 
estimated for a patient weight of 5 kg. After de-airing and 15 minutes circulating at 320C,
200 ml whole blood was added to each system. During the circulation the flow was kept 
at 0,60 liters per minute (l/min) with a pressure between 25 – 30 mmHg. The flow 
through the ultrafilter was kept at 0,10 l/min during the circulation and 0,15 l/min with a 
pressure of 50 mmHg during ultrafiltration. 
Samples ( table 1) 
After priming and de-airing the prime was warmed to 320 C. Ten minutes later 5 mg of 
dexamethasone was added to the clear prime in the dexamethasone group and 5 minutes 
after that sample 1 was collected. Five minutes after adding the blood sample 2 was 
collected and the prime was cooled to 280 C. After 50 minutes circulation at 280 C sample 
3 was collected and the prime was rewarmed to 370 C. Fifteen minutes later sample four 
was collected and ultrafiltration was started for 10 minutes. After ultrafiltration sample 5  
Table 1. sample measurements 
and a sample of the ultrafiltrate were collected. Al samples were collected in EDTA (BD, 
San Jose, CA, USA). protected from light, immediately cooled, transported to the 
laboratory and centrifuged ( 15  min, 40C, 1550 g). The plasma was aliquoted and stored 
at -800C.
Laboratory measurements (table 1) 
Dexamethasone concentrations were measured by radioimmunoassay (IgG Corporation 
Nashville, TN, USA) following a slightly modified protocol.6 Interleukins IL-6, 8, and 10 
were measured using a commercial enzyme immunoassay (PeliKine®, Sanquin Reagents 
Measurement/ 
Sample no 
IL-6 IL-8 IL-10 Dexamethasone
1     x 
2  x x x x 
3 x x x x 
4 x x x x 
5 x x x x 
ultrafiltrate x x x x 
75
Material and Methods 
Ten units of fresh whole blood were delivered by our blood bank (Sanquin, Leiden, The 
Netherlands) and used for 20 separate in vitro experimental circulations. Five hundred ml 
of whole blood was collected in a bag containing citrate-phosphate-dextrose (70 ml) as 
anticoagulant and cooled directly to 220C. Written informed consent of the blood donors 
was obtained. Every blood bag was used for 2 circulations (200 ml for each run), in an 
uncoated system and in a coated system. Four experimental circulation groups were 
studied, 5 uncoated systems without dexamethasone (UND), 5 coated systems without 
dexamethasone (CND), 5 uncoated systems with dexamethasone (UWD) and 5 coated 
systems with dexamethasone (CWD).  
Bypass system and prime procedure 
For all circulations a Dideco Lilliput D901® (Dideco, Mirandola, Italy) with integrated 
soft shell venous reservoir was used. The PHISIO® coated system were completely 
coated ‘from tip to tip’. A Stockert® SIII rollerpump (Stockert Instrumente Gmbh, 
Munich, Germany) was used inducing nonpulsatile flow. At the end of the circulation 
ultrafiltration was performed with a Jostra BC 20 plus® (Maquet CP, Hirrlingen, 
Germany) imitating modified ultrafiltration.  
All systems were primed with 100 ml 20% human albumin (Octapharma, Vienna, 
Austria) 200 ml Ringers’ solution, 5 ml 20% mannitol (Baxter BV NL, Utrecht, The 
Netherlands) and 1000 IE Heparin (LEO Pharma, Breda, The Netherlands) imitating the 
standard prime composition used in our institution. In the dexamethasone groups 5 mg 
dexamethasone (Pharmacy, Leiden University Medical Center (LUMC), The 
Netherlands) was added to the prime. Doses of mannitol and dexamethasone were 
estimated for a patient weight of 5 kg. After de-airing and 15 minutes circulating at 320C,
200 ml whole blood was added to each system. During the circulation the flow was kept 
at 0,60 liters per minute (l/min) with a pressure between 25 – 30 mmHg. The flow 
through the ultrafilter was kept at 0,10 l/min during the circulation and 0,15 l/min with a 
pressure of 50 mmHg during ultrafiltration. 
Samples ( table 1) 
After priming and de-airing the prime was warmed to 320 C. Ten minutes later 5 mg of 
dexamethasone was added to the clear prime in the dexamethasone group and 5 minutes 
after that sample 1 was collected. Five minutes after adding the blood sample 2 was 
collected and the prime was cooled to 280 C. After 50 minutes circulation at 280 C sample 
3 was collected and the prime was rewarmed to 370 C. Fifteen minutes later sample four 
was collected and ultrafiltration was started for 10 minutes. After ultrafiltration sample 5  
Table 1. sample measurements 
and a sample of the ultrafiltrate were collected. Al samples were collected in EDTA (BD, 
San Jose, CA, USA). protected from light, immediately cooled, transported to the 
laboratory and centrifuged ( 15  min, 40C, 1550 g). The plasma was aliquoted and stored 
at -800C.
Laboratory measurements (table 1) 
Dexamethasone concentrations were measured by radioimmunoassay (IgG Corporation 
Nashville, TN, USA) following a slightly modified protocol.6 Interleukins IL-6, 8, and 10 
were measured using a commercial enzyme immunoassay (PeliKine®, Sanquin Reagents 
Measurement/ 
Sample no 
IL-6 IL-8 IL-10 Dexamethasone
1     x 
2  x x x x 
3 x x x x 
4 x x x x 
5 x x x x 
ultrafiltrate x x x x 
76
(Sanquin, Amsterdam, Netherlands)). All assays were performed according to the 
manufacturers instructions.  
Statistical analysis 
Data were analysed with the statistical package SPSS v11.5 (SPSS Software Inc., 
Chicago, IL, USA). Data are summarized as mean + Standard Deviation (SD) unless 
stated otherwise. Dexamethasone concentrations as well as changes in IL-8 were 
analyzed with repeated ANOVA measures using the Greenhouse-Geisser correction. 
Repeated measures analysis for dexamethasone concentrations were tested against and 
without values in the ultrafiltrate. As IL-8 values were not normally distributed,  these 
data were first subjected to a natural logarithmic transformation before analysis by 
repeated ANOVA measures. P < 0,05 was considered statistically as significant. 
 Figure 1. Changes in 
dexamethasone concentrations at 
different sampling times and in the 
ultrafiltrate. Uncoated ( ) and 
coated ( ) bypass circuit. Values 
expressed as mean (SD). 
1 2 3 4 5 6

















Changes in dexamethasone concentrations throughout the study period are presented in 
relative (Table 2) and absolute (Table 3) values, and as a graphic representation in figure 
2. After addition of 5 mg of dexamethasone, 7 to 10% of the total dose was present as 
free fraction in the prime. There was an absolute reduction of free dexamethasone 
following the addition of blood to the prime. This trend was reversed after cooling (0.34 
mg in NWD and 0.33 mg in CWD) with a further increase after rewarming (0.42 mg in 
NWD and 0.38 mg in CWD). Absolute concentrations of dexamethasone increased 
further after ultrafiltration. Changes in dexamethasone concentrations were significant 
throughout the study period within each group. Coating did not significantly affect 
dexamethasone disposition throughout the study. Dexamethasone was also found in the 
ultrafiltrate (approximately 2% of the total dose).
Table 2: Dexamethasone concentrations in nmol/l 
 1 2 3 4 5 UF 
UWD* 1269 (149) 751 (79) 879 (93) 1065 (276) 1696 (218) 239 (51) 
CWD* 957 (215) 667 (45) 857 (148) 980 (143) 1650 (143) 209 (33) 
Changes in dexamethasone concentrations at different sampling times and in the ultrafiltrate (UF). Values 
expressed as mean (SD) in nmol/l. * Statistical significance within groups. 
Table 3: Dexamethasone concentrations in mg 
 1 2 3 4 5 UF 
UWD* 0,49 (0,06) 0,29 (0,03) 0,34 (0,03) 0,42 (0,10) 0,66 (0,08) 0,09 (0,02) 
CWD* 0,37 (0,08) 0,26 (0,02) 0,33 (0,06) 0,38 (0,02) 0,64 (0,05) 0,08 (0,01) 
Changes in dexamethasone concentrations at different sampling times and in the ultrafiltrate (UF). Values 
expressed as mean (SD) in mg. * Statistical significance within groups. 
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Interleukines
Interleukins IL-6 and IL-10 were not detectable. IL-8 was only detectable at the sample 
moments 3, 4 and 5 and in some ultrafiltration (UF) samples (Table 4). Overall no 
significant differences were observed except in the group of coated systems without 
dexamethasone (CND). This group showed a significantly higher IL-8 production. The 
concentration of IL-8 increased after ultrafiltration. IL-8 was also found in the 
ultrafiltrate if the concentration was high (> 20 pg/ml) in the prime before ultrafiltration.  
Table 4: IL-8 Changes 
Sample moment  UND CND UWD CWD 
3 0,80 (0,70) 1,95 (2,00) ND 1,82 (1,18) 
4 2,38 (1,36) 9,70 (8,20)† 5,30 (2,70) 5,70 (3,60) 
5 11,00 (4,50) 24,10 (20,40) † 11,30 (6,70) 16,30 (6,90) 
Changes in IL-8 according to combinations of coated/uncoated plus/minus dexamethasone.  UND 
(uncoated without dexamethasone), CND (coated without dexamethasone), UWD (uncoated with 
dexamethasone) and CWD (coated with dexamethasone). ND not detectable. Values expressed as mean 
(SD) in pg/ml. † Denotes statistical significance between groups. 
Discussion
In the present study we measured changes of dexamethasone concentrations in the prime 
in coated and uncoated CPB systems as well as the effect of dexamethasone and coating 
on the production of cytokines in both phosphorylcholine coated and uncoated systems. 
To our knowledge these interactions have not been previously investigated.
In pediatric cardiac surgery the use of steroids has not been investigated to the same 
extent as in adults, and its use is as controversial. Nevertheless steroids are used widely in 
pediatric cardiac surgery and its use remains controversial.7 There is evidence in the 
literature that steroids given before the start of CPB  reduce the pro-inflammatory 
mediators in adult and pediatric cardiac surgery alike.2,8 Bronicki and colleagues showed 
in a prospective randomized study, that dexamethasone administered prior to CPB led to 
a reduction in the post bypass inflammatory response as assessed by cytokine levels.2
Butler et al investigated the level of cytokines during CPB and the effect of intraoperative 
methylprednisolone at a dose of 10 mg/kg in a pediatric group.8 IL-6 concentrations were 
higher and peaked earlier in the group without steroids. It has also been proven that 
dexamethasone decreases the pro- to anti-inflammatory cytokine ratios during adult 
cardiac surgery.9 At this moment no consensus exists on which steroid and which doses 
should be used. It has also been shown that steroids reduce the production of C-reactive 
protein without any effect on the release of protein S100B and Von Willebrand factor.10
The concentration of proinflammatory cytokines decreases when steroids are 
administered before CPB starts.8 The reduction is even more remarkable if steroids are 
given before and during CPB.11 Oxygen delivery and cardiac output increased more 
rapidly when steroids were used in an animal model.12 Even the timing of the 
administration seems to be relevant.13
Drug disposition of hydrocortisone in a in vitro model of ECMO (Extracorporeal 
membrane oxygenation) has been evaluated recently.14 The authors recorded more than 
20% loss after 30 minutes in a crystalloid-prime circuit. Drug disposition can be affected 
by CPB, this subject has been reviewed elsewhere.15 We were not able to find any study 
assessing the effect of CPB on concentrations of dexamethasone either in vivo or in vitro.
In the present study the reduction of free dexamethasone after the addition of whole 
blood to the prime may be explained by dilution and by binding to proteins in the blood 
product. We have no explanation as to why the concentration of free dexamethasone 
increased after cooling and continued to rise after rewarming. Hemoconcentration after 
modified ultrafiltration explains only partly the further rise of free dexamethasone in 
absolute values. Of interest is that nearly 2% of the total dose of dexamethasone is lost in 
the ultrafiltrate fluid.  
Coating of the cardiopulmonary bypass has been developed to reduce systemic 
inflammation during cardiopulmonary bypass. We were unable to show any differences 
between the uncoated and the coated systems except for IL-8 which was significantly 
higher in the coated group without dexamethasone. IL-8 was found only in 3 of the 5 
sample times. In vitro studies performed by other groups showed significant differences
and improvement of biocompatibility for the coated groups. 16,17
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sample times. In vitro studies performed by other groups showed significant differences
and improvement of biocompatibility for the coated groups. 16,17
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Previous studies have shown that isolated CPB induces an increase in IL-8 [16]. It is not 
surprising that in our study IL-10 was undetected. Previous investigators have shown that 
an in vitro model is unable to generate anti-inflammatory cytokines.18 
The fact that IL-6 was undetected in our study may be due to differences in methodology. 
Two hundred ml’s of whole blood were added to the prime. It can be speculated that this 
amount of blood was not enough to generate the production of IL-6. Blood added to the 
prime had been preserved with sodium citrate. Flower and colleagues found that levels of 
IL-6 were significantly lower when sodium citrate was used although De Jongh and 
colleagues could not reproduce their findings.19,20 IL-8 was regularly detectable in 3 of 
the 5 sample moments  (3, 4 and 5). There were no significant differences except for the 
coated group without dexamethasone. Increases in IL-8 after ultrafiltration can be partly 
explained by hemoconcentration: not all the UF samples contained IL-8. IL-8 is produced 
by activated neutrophils, monocytes and T-cells. Fung et al. found that the IL-8
production was dependant on temperature.21 At lower temperatures the levels did not 
increase. In our study, after rewarming of the prime to 37oC, we measured an increase of 
Il-8 in all groups which was more pronounced in the coated group without 
dexamethasone. Gormley and colleagues measured IL-8 in an “adult” in vitro model of 
CPB with a control group and after addition of methylprednisolone to the prime.22 These 
investigators found peaks of more than 35 pg/ml of IL-8 in the control group. The 
addition of methylprednisolone reduced the IL-8 concentration in the samples  
significantly.
In a previous study we compared a phosphorylcholine coated cardiopulmonary bypass 
system with an uncoated system in pediatric patients undergoing cardiac surgery.5 The 
use of phosphorylcholine coated system did not affect  C3b/c, elastase HNE, Il-6 and 
CRP.  Horton and co-workers also were not able to show any differences between a 
heparin coated system and an uncoated system in a study population of 200 patients.23
In conclusion our study shows that there is no interaction between the phosphorylcholine 
coating and dexamethasone and a small part of dexamethasone is lost into the 
ultrafiltrate. We also showed that in the group with PHISIO® coating the production of 
IL-8 was increased significantly, IL-6 was not detected. Our study confirms that an in 
vitro model is unable to trigger the production of IL-10. We document for the first time  
dexamethasone disposition  in a  CPB circuit.  
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A systemic inflammatory response after pediatric cardiac surgery is not uncommon. The 
cardiopulmonary bypass (CPB) circuit is seen as the main activator of the inflammatory 
response. For that reason, several coatings have been developed to create a more 
biocompatible CPB circuit. At this moment, several coatings are commercially available: 
human albumin coating, Duraflo II and Carmeda coatings (both based on heparin), 
phosphorylcholine PHISIO coating (which mimics the outer cell membrane), 
polymethoxyethylacrylate coating, and the biopassive surface Trillium coating. 
Do these coatings result in less inflammatory response after pediatric cardiac surgery? In 
reviewing the literature on coating of pediatric CPB circuits, a lot of controversies are 
found. In vitro studies show significantly better biocompatibility of coated circuits than 
of noncoated circuits [1-3]. The outcomes of in vivo or clinical studies are less 
convincing; many times only a few parameters show improvement [4–7]. Some of the 
problems found in reviewing studies on coatings are: different methodologies, lack of 
proper control groups, differences between the patients concerning age and bodyweight, 
and different prime volumes in different groups. Furthermore, measured parameters are 
numerous, and sample moments show large variability (table 1). 
In the adult population, many more studies on coatings have been published. Here, we 
find more evidence for beneficial effects of coatings, but it is not clear whether the results 
of these studies can simply be extrapolated to the practice of pediatric cardiac surgery 
[13].
Several factors may cause an inflammatory response. The artificial surface of the CPB 
circuit is an important activator, but other activators are probably as important: ischemia-
reperfusion, surgical trauma (especially that of cardiovascular surgery), endotoxemia, and 
blood–air contact [14]. Patients that have cardiovascular operations without the use of 
CPB have been reported to show also signs of serious inflammatory response [15–17]. 
Although CPB is not the only causative factor for an inflammatory response, coating of 
the CPB circuit is expected to result in improved biocompatibility with less activation of 
the complement system, the contact system, as well as a reduced activation of leucocytes 
and platelets. 
To what should we thus adhere? In vitro studies provide the most reliable information 
because of their controlled environment and similar outcomes. The most important for 
clinical studies is a homogeneous patient group, especially in the pediatric population 
where a wide spread in age, bodyweight, and diagnosis is commonly encountered. 
Table 1. Pediatric In Vivo Studies: Randomized and Prospective 
Authors Year N Measurements 
Schreurs et al. [8] 1998 19 Less platelet activation/ complement activation similar 
Jensen et al. [9] 2004 40 Fibrinolysis reduced/ inflammatory parameters not 
measured 
Grossi et al. [10] 2000 23 Less C3a, IL-8/ similar C5a, IL-6 
Olsson et al. [11] 2000 19 Less C3a, C5b-9, and IL-6 
Ashraf et al. [12] 1997 21 Less C5b-9, elastase, (IL-6)/ similar IL-8 
Horton et al. [4] 1999 200 Similar IL-6, IL-8, and platelets 
Our group recently performed a prospective, randomized, and blinded clinical study in 28 
neonates and small infants to compare complement activation and leucocytes stimulation 
of phosphorylcholine coated and noncoated CPB circuits. Strict inclusion criteria were 
used: bodyweight between 3 and 6 kg, no syndromal anomalies such as Down syndrome, 
no severe cyanosis (oxygen saturation < 75%), no circulation arrest, no reoperations, and 
no premature patients. All patients received the same protocolized way of anesthesia and 
CPB management; none of the patients received aprotinin or other drugs that might 
interfere with the inflammatory response. No ultrafiltration, conventional or modified, 
was used in the study patients. No differences were observed between the two groups for 
the changes of complement factor C3b/c, elastase HNE, interleukin-6, and C-reactive 
protein before, during, and after CPB until 6 hours postoperatively. We concluded that 
phosphorylcholine coating does not result in a reduction of inflammatory response (data 
not shown). 
Summarizing the review of the literature and our study, we conclude that an improved 
biocompatibility by coating is most reliably demonstrated by in vitro studies, whereas 
clinical studies in the pediatric population do not show equally convincing beneficial 
effects. More strictly protocolized randomized prospective clinical studies will be needed 
to gather evidence for positive effects of CPB circuit coating in pediatric cardiac surgery. 
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In the meantime, we should realize that coating alone cannot lead to an adequate 
reduction of inflammatory response. Other agents should be considered for this purpose, 
such as ultrafiltration during and/or after CPB, corticosteroids and protease inhibitors, 
and the use of monoclonal antibodies [18]. Efforts to further miniaturize the pediatric 
CPB-circuit will also be helpful.  
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In the meantime, we should realize that coating alone cannot lead to an adequate 
reduction of inflammatory response. Other agents should be considered for this purpose, 
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SUMMARY
Cardiopulmonary bypass (CPB) is a technique that makes open heart surgery possible. 
When CPB is used the heart can be stopped while the blood circulation, oxygen delivery 
and carbon dioxide removal are guaranteed. In the last decades CPB has become much 
safer  but still causes a systemic inflammation reaction (SIRS). SIRS may cause 
morbidity and, when severe, even mortality. SIRS reaction is worse in neonates and 
infants due to the immaturity of organs and the unfavourable ratio of CPB prime volume 
to patient circulating volume.  This thesis focuses on different techniques that have been
developed to decrease the deleterious effects of CPB in pediatric cardiac surgery. 
In chapter 2 we describe the technique of modified ultrafiltration (MUF). This technique, 
described for the first time in 1991 by Naik and Elliott, is designed to reverse the 
hemodilution created during CPB. After the cessation of CPB excess water is removed by 
using an ultrafilter thus providing a higher hematocrit at the end of the procedure. We 
compared in a retrospective way 2 groups of 99 patients each, in one group we used MUF 
and in the other group ultrafiltration was not used. We concluded that modified 
ultrafiltration decreases blood transfusion requirements and chest drain loss after 
pediatric cardiac surgery. 
The ratio between CPB prime solution and circulating blood volume is highest in the 
neonatal patient. It has been reported that neonates have a poor antioxidative and iron 
binding capacity. During CPB, prooxidative substances, such as nonprotein-bound iron, 
are released while the plasma antioxidant capacity decreases, resulting in excess 
accumulation of deze afkorting voluit opschrijven!Radical Oxygen Species. In chapter 3 
and 4 we describe the antioxidative capacity of CPB prime based on human albumin or 
fresh frozen plasma. We have demonstrated that a prime based on fresh frozen plasma 
has  higher antioxidative and  iron, Hb/Heam binding capacities. 
Contact of blood with the non-biological surfaces of the CPB system has been designated 
as the main cause of complement activation. Improving the biocompatibility of CPB 
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systems by means of decreasing the contact activation of blood elements and thereby 
attenuating the inflammatory response is evidently desired, and for this reason several 
coatings have been developed. In chapter 5 we investigated the PHISIO® coating in 
neonatal CPB.  We were not able to show any differences between a coated and an 
uncoated CPB system in this prospective randomized study. 
In chapter 6 we describe the results of the use of dexamethasone in both coated and 
uncoated CPB systems. Information is lacking about the interaction of medication and the 
CPB prime or  the coating of a CPB system. We did not observe any interaction between 
dexamethasone and the PHISIO® coating, but have  observed  that in the group with 
PHISIO® coating without dexamethasone the production of IL-8 was significantly 
increased.
In literature many controversies are found on the topic of CPB coatings. It is difficult to 
compare these studies due to different patient groups, differences in measured parameters 
and lack of proper control groups. Chapter 7 reviews the literature on the use of CPB 
coatings both in vitro and in vivo. 
SAMENVATTING
Cardiopulmonale bypass (CPB) is een techniek die open hart chirurgie mogelijk maakt. 
Wanneer CPB wordt gebruikt kan de hartactie worden gestopt terwijl de bloedcirculatie 
en zuurstof afgifte gewaarborgd blijft. Ondanks dat in de laatste decennia CPB een 
veiliger procedure is geworden blijft CPB een algehele onstekingsreactie veroorzaken. 
Deze ontstekingsreactie kan morbiditeit en in sommige gevallen zelfs mortaliteit tot 
gevolg hebben. De ontstekingsreactie is ernstiger bij neonaten en zuigelingen omdat hun 
organen nog niet volgroeid zijn en omdat de ratio CPB prime volume tot circulerende 
volume hier het minst gunstig is. Dit proefschrift richt zich op de verschillende 
technieken die zijn ontwikkeld om de nadelige gevolgen van pediatrische CPB te 
verminderen. 
In hoofdstuk 2 wordt de techniek van gemodificeerde ultrafiltratie (MUF) beschreven. 
Deze techniek werd voor het eerst beschreven in 1991 door Naik en Elliott en is 
ontworpen om de hemodilutie die ontstaat door het gebruik van de hart-longmachine te 
verminderen (REF). Wanneer de hart-longmachine is gestopt wordt het teveel aan water 
onttrokken door middel van een hemofilter. Wij vergeleken in een retrospectief 
onderzoek twee groepen van 99 patientjes ieder waarbij in de ene groep wel MUF werd 
gebruikt en in de andere groep niet. Wij vonden dat met MUF de hoeveelheid gebruikt 
donorbloed significant minder was terwijl het postoperatieve bloedverlies ook afnam. 
Het verschil in het prime volume van de hart-longmachine en het bloedvolume van het 
kind is groot. We weten ook dat neonaten en pasgeborenen een lage anti-oxidatieve 
capaciteit hebben en een lage capaciteit om vrij ijzer te binden. Tijdens het gebruik van 
de hart-longmachine worden pro-oxidatieve stoffen zoals vrij ijzer gevormd terwijl de 
capaciteit in het plasma om dit te binden verminderd. Hierdoor ontstaan er reactieve 
oxidatie deeltjes. In hoofdstuk 3 en 4 beschrijven wij de anti-oxidatieve capaciteit van 
twee verschillende samenstellingen  van de prime, één gebaseerd op menselijke albumine 
en één gebaseerd op fresh frozen plasma. Wij toonden aan dat de CPB prime gebaseerd 
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op fresh frozen plasma een hogere anti-oxidatieve capaciteit had en beter in staat was om 
vrij ijzer te binden. 
Het contact van bloed met het lichaamsvreemde oppervlak van de hart-longmachine 
wordt gezien als de belangrijkste activator van de algehele onstekingsreactie. Deze 
reactie zou verminderd kunnen worden als het bloed de hart-longmachine niet meer als 
lichaamsvreemd herkent. Hiertoe worden de kunstlong en de slangen van de hart-
longmachine bekleed met een minder lichaamsvreemde stof, dit wordt coating genoemd. 
In hoofdstuk 5 bestudeerden wij de PHISIO® coating in neonatale CPB. Wij waren niet 
in staat om aan te tonen dat er verschil was in de mate van ontstekingsreactie  tussen de 
gecoate hart-longmachine en de ongecoate in deze prospectieve en gerandomiseerde 
studie.
In hoofdstuk 6 beschrijven we de resultaten van het onderzoek naar de interactie van 
dexamethason en de coating van het CPB systeem. Er is weinig bekend over de interactie 
tussen medicijnen en de CPB prime of met de coating van het systeem. We vonden geen 
interactie tussen dexamethason en de PHISIO® coating, maar we vonden wel in de groep 
met PHISIO® coating zonder dexamethason een verhoogde IL-8 productie. 
In de literatuur bestaan er veel verschillen tussen de verschillende studies over het 
onderwerp CPB coatings. Het is lastig om deze studies te vergelijken door de verschillen 
in patiëntengroepen, verschil in de gemeten parameters en het gemis aan een goede 
controle groep. Hoofdstuk 7 in een literatuur review over het gebruik van coating in 
zowel in vitro als in vivo onderzoeken. 
DANKWOORD
Een dankwoord is een lastig iets. De kans dat je iemand vergeet om te bedanken is groot. 
Vele mensen binnen, maar zeker ook buiten het ziekenhuis, hebben mij aangemoedigd, 
geholpen en bijgestaan. Ik ben niet in staat om iedereen persoonlijk te bedanken of te 
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Bruggemans, bedankt voor alle gezellige uren en pizza’s tijdens de besprekingen van de 
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aanmoedigen en ik dank je voor het nakijken van de artikelen. Mijn collega 
perfusionisten wil ik bedanken voor hun ondersteuning, met speciale dank naar Gonda en 
Eelco, jullie geduld met mij was eindeloos. Ook de collega’s van cluster 3 wil ik danken 
voor hun ondersteuning en enthousiasme. Verder de artsen en de verpleegkundigen van 
de kinder intensive care. Ook de analisten van alle verschillende laboratoria wil ik 
bedanken, voor het uitvoeren van de bepalingen maar vooral ook voor het meedenken, 
voor het laatste wil ik vooral Fred Romijn bedanken. 
Ruben, Jochem en Jelmer, jullie aanwezigheid alleen al was de grootste stimulans om 
door te gaan. Het beste bewaar je altijd voor het laatst: Vanessa, dank je wel voor je 
geloof en vertrouwen in me. 
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